

sp p  
su CL v/c filed 06/20/1998, now abandon.

ARTIFICIAL T HELPER CELL EPITOPES AS IMMUNE  
STIMULATORS FOR SYNTHETIC PEPTIDE IMMUNOGENS

This is a Continuation-In-Part of application No. 09/100,412,  
FIELD OF THE INVENTION

This invention relates to a peptide immunogen  
5 comprising a novel artificial T helper cell epitope (Th)  
covalently linked to a desired target antigenic site  
comprising B cell epitopes and optionally a general immune  
stimulator sequence. The artificial Th epitope imparts to the  
peptide immunogen the capability to induce strong T helper  
10 cell-mediated immune responses and the production of  
antibodies directed against the "target antigenic site." The  
invention also provides for the advantageous replacement of  
carrier proteins and pathogen-derived T helper cell sites in  
established peptide immunogens by the novel artificial T  
15 helper cell epitopes for improved immunogenicity.

Many rules have been developed for predicting the  
amino acid sequences of T cell epitopes. However, because  
there is no central unifying theory on how or what makes a  
particular amino acid sequence useful as a T cell epitope, the  
20 rules are empirical and are not universally applicable. Being  
aware of these rules, the novel artificial T helper cell  
epitopes of the present invention were developed,  
nevertheless, by empirical research.

The peptide immunogens of the present invention are  
25 useful for evoking antibody responses in an immunized host to  
a desired target antigenic site, including sites taken from  
pathogenic organisms, and sites taken from normally  
immunosilent self-antigens and tumor-associated targets.  
Accordingly, the peptides of the invention are useful in  
30 diverse medical and veterinary applications, such as:  
vaccines to provide protective immunity from infectious  
disease; immunotherapies for treating disorders resulting from  
malfunctioning normal physiological processes; immunotherapies  
for treating cancer and as agents to intervene in normal  
35 physiological processes to produce desirable results.

For example, the novel artificial T helper cell epitopes of the present invention provide novel short peptide immunogens that elicit antibodies targeted to luteinizing hormone-releasing hormone (LHRH) and are useful for

5 contraception, control of hormone-dependent tumors, prevention of boar taint, and immunocastration. The novel artificial Th epitopes of the present invention have been found to provoke an immune response when combined with target B cell epitopes of various microorganisms/proteins/peptides. In addition to

10 LHRH, the artificial Th epitopes of the present invention have been found to be useful when linked to other target antigenic sites including somatostatin for growth promotion in farm animals; IgE for treatment of allergy; the CD4 receptor of T helper cells for treatment and prevention of HIV infection and

15 immune disorders; foot-and-mouth disease virus capsid protein for prevention of foot-and-mouth disease; HIV virion epitopes for prevention and treatment of HIV infection; the circumsporozoite antigen of *Plasmodium falciparum* for prevention and treatment of malaria; and Cholesteryl ester

20 transport protein (CETP) for prevention and treatment of arteriosclerosis.

CL c/c

#### BACKGROUND OF THE INVENTION

It is known that most antibody immune responses are cell-mediated, requiring cooperative interaction between

25 antigen-presenting cells, B cells (antibody-producing cells which also function as antigen-presenting cells), and T helper (Th) cells. Consequently, the elicitation of an effective antibody response requires that the B cells recognize the target antigenic site (B cell epitope) of a subject immunogen

30 and the T helper cells recognize a Th epitope. Generally, the T helper epitope on a subject immunogen is different from its B cell epitope(s) (Babbitt et al., *Nature*, 1985; 317: 359-361). The B cell epitope is a site on the desired target recognized by B cells which in response produce antibodies to

35 the desired target site. It is understood that the natural

conformation of the target determines the site to which the antibody directly binds. The T helper cell recognition of proteins is, however, much more complex and less well understood. (Cornette et al., in *Methods in Enzymology*, vol 5 178, Academic Press, 1989, pp 611-634).

Under present theories, evocation of a Th cell response requires the T helper cell receptor to recognize not the desired target but a complex on the membrane of the antigen-presenting cell formed between a processed peptide 10 fragment of the target protein and an associated class II major histocompatibility complex (MHC). Thus, peptide processing of the target protein and a three-way recognition is required for the T helper cell response. The three part complex is particularly difficult to define since the critical 15 MHC class II contact residues are variably positioned within different MHC binding peptides (Th epitopes) and these peptides are of variable lengths with different amino acid sequences (Rudensky et al., *Nature*, 1991; 353:622-627). Furthermore, the MHC class II molecules themselves are highly 20 diverse depending on the genetic make-up of the host. The immune responsiveness to a particular Th epitope is thus in part determined by the MHC genes of the host. In fact, it has been shown that certain peptides only bind to the products of particular class II MHC alleles. Thus, it is difficult to 25 identify promiscuous Th epitopes, i.e., those that are reactive across species and across individuals of a single species. It has been found that the reactivity of Th epitopes is different even among individuals of a population.

The multiple and varied factors for each of the 30 component steps of T cell recognition: the appropriate peptide processing by the antigen-processing cell, the presentation of the peptide by a genetically determined class II MHC molecule, and the recognition of the MHC molecule/peptide complex by the receptor on T helper cells have made it difficult to determine 35 the requirements for promiscuous Th epitopes that provide for broad responsiveness (Bianchi et al., EP 0427347; Sinigaglia

et al., chapter 6 in *Immunological Recognition of Peptides in Medicine and Biology*, ed., Zegers et al., CRC Press, 1995, pp 79-87).

It is clear that for the induction of antibodies, the immunogen must comprise both the B cell determinant and Th cell determinant(s). Commonly, to increase the immunogenicity of a target, the Th response is provided by coupling the target to a carrier protein. The disadvantages of this technique are many. It is difficult to manufacture well-defined, safe, and effective peptide-carrier protein conjugates for the following reasons:

1. Chemical coupling are random reactions introducing heterogeneity of size and composition, e.g., conjugation with glutataraldehyde (Borras-Cuesta et al., *Eur J Immunol*, 1987; 17: 1213-1215);
2. the carrier protein introduces a potential for undesirable immune responses such as allergic and autoimmune reactions (Bixler et al., WO 89/06974);
3. the large peptide-carrier protein elicits irrelevant immune responses predominantly misdirected to the carrier protein rather than the target site (Cease et al., *Proc Natl Acad Sci USA*, 1987; 84: 4249-4253); and
4. the carrier protein also introduces a potential for epitopic suppression in a host which had previously been immunized with an immunogen comprising the same carrier protein. When a host is subsequently immunized with another immunogen wherein the same carrier protein is coupled to a different hapten, the resultant immune response is enhanced for the carrier protein but inhibited for the hapten (Schutze et al., *J Immunol*, 1985; 135: 2319-2322).

To avoid these risks, it is desirable to replace the carrier proteins. T cell help may be supplied to a target antigen peptide by covalent binding to a well-characterized promiscuous Th determinant. Known promiscuous Th are derived from the potent pathogenic agents such as measles virus F

protein (Greenstein et al., *J Immunol*, 1992; 148: 3970-3977) and hepatitis B virus surface antigen (Partidos et al., *J Gen Virol* 1991; 72: 1293-1299). The present inventors have shown that many of the known promiscuous Th are effective in potentiating a poorly immunogenic peptide, such as the decapeptide hormone luteinizing hormone-releasing hormone (LHRH) (US 5,759,551). Other chimeric peptides comprising known promiscuous Th epitopes with poorly immunogenic synthetic peptides to generate potent immunogens have been developed (Borras-Cuesta et al., 1987). Well-designed promiscuous Th/B cell epitope chimeric peptides are capable of eliciting Th responses with resultant antibody responses targeted to the B cell site in most members of a genetically diverse population (US 5,759,551).

A review of the known promiscuous Th epitopes shows that they range in size from approximately 15 to 50 amino acid residues (US 5,759,551) and often share common structural features with specific landmark sequences. For example, a common feature is the presence of amphipathic helices. These are alpha-helical structures with hydrophobic amino acid residues dominating one face of the helix and charged and polar residues dominating the surrounding faces (Cease et al., 1987). Known promiscuous Th epitopes also frequently contain additional primary amino acid patterns such as a charged residue, -Gly-, followed by two to three hydrophobic residues, followed in turn by a charged or polar residue (Rothbard and Taylor, *EMBO J*, 1988; 7:93-101). Th epitopes with this pattern are called Rothbard sequences. It has also been found that promiscuous Th epitopes often obey the 1, 4, 5, 8 rule, where a positively charged residue is followed by hydrophobic residues at the fourth, fifth and eighth positions, consistent with an amphipathic helix having positions 1, 4, 5 and 8 located on the same face. This pattern of hydrophobic and charged and polar amino acids may be repeated within a single Th epitope (Partidos et al., *J Gen Virol*, 1991; 72:1293-99).

Most, if not all, of the known promiscuous T cell epitopes contain at least one of the periodicities described above.

Promiscuous Th epitopes derived from pathogens include the hepatitis B surface and core antigen helper T cell epitopes (HBsAg Th and HBc Th), the pertussis toxin helper T cell epitopes (PT Th), the tetanus toxin helper T cell epitopes (TT Th), the measles virus F protein helper T cell epitopes (MVF Th), the *Chlamydia trachomatis* major outer membrane protein helper T cell epitopes (CT Th), the diphtheria toxin helper T cell epitopes (DT Th), the *Plasmodium falciparum* circumsporozoite helper T cell epitopes (PF Th), the *Schistosoma mansoni* triose phosphate isomerase helper T cell epitopes (SM Th), and the *Escherichia coli* TraT helper T cell epitopes (TraT Th). The sequences of these pathogen-derived Th epitopes can be found in US 5,759,551 as SEQ ID NOS:2-9 and 42-52 therein, incorporated herein by reference; in Stagg et al., *Immunology*, 1993; 79:1-9; and in Ferrari et al., *J Clin Invest*, 1991; 88: 214-222, also incorporated by reference.

The use of such pathogen-derived sites for the immuno-potentiation of peptide B cell sites for application to LHRH has been described in US 5,759,551, for HIV in Greenstein et al. (1992), for malaria in EP 0 427,347, for rotavirus in Borrás-Cuesta et al. (1987), and for measles in Partidos et al. (1991).

Useful Th epitopes may also include combinatorial Th epitopes. In Wang et al. (WO 95/11998), a particular class of combinatorial Th epitopes, a "Structured Synthetic Antigen Library" (SSAL) was described. Th SSAL epitopes comprise a multitude of Th epitopes with amino acid sequences organized around a structural framework of invariant residues with substitutions at specific positions. The sequences of the SSAL are determined by retaining relatively invariant residues while varying other residues to provide recognition of the diverse MHC restriction elements. This may be accomplished by

aligning the primary amino acid sequence of a promiscuous Th, selecting and retaining as the skeletal framework the residues responsible for the unique structure of the Th peptide, and varying the remaining residues in accordance with known MHC restriction elements. Lists of the invariant and variable positions with the preferred amino acids of MHC restriction elements are available to obtain MHC-binding motifs. These may be consulted in designing SSAL Th epitopes (Meister et al., Vaccine, 1995; 13:581-591).

The members of the SSAL may be produced simultaneously in a single solid-phase peptide synthesis in tandem with the targeted B cell epitope and other sequences. The Th epitope library sequences are designed to maintain the structural motifs of a promiscuous Th epitope and at the same time, accommodate reactivity to a wider range of haplotypes. For example, the degenerate Th epitope "SSAL1 TH1" (WO 95/11998), was modeled after a promiscuous epitope taken from the F protein of the measles virus (Partidos et al., 1991 ). SSAL1 TH1 was designed to be used in tandem with a target antigen, LHRH. Like the measles epitope from which it was derived, SSAL1 TH1 was designed to follow the Rothbard sequence and the 1, 4, 5, 8 rules and is a mixture of four peptides:

|    |   |             |             |             |     |
|----|---|-------------|-------------|-------------|-----|
| 25 | 1   | 5           | 10          | 15          |     |
|    | Asp-Leu-Ser-Asp-Leu-Lys-Gly-Leu-Leu-Leu-His-Lys-Leu-Asp-Gly-Leu |             |             |             |     |
|    | (SEQ ID NO:2)   |             |             |             |     |
|    | Glu Ile   | Glu Ile Arg | Ile Ile Ile | Arg Ile Glu | Ile |
|    | (SEQ ID NO:3)   |             |             |             |     |
| 30 | Val   | Val         | Val Val Val | Val         | Val |
|    | (SEQ ID NO:4)   |             |             |             |     |
|    | Phe   | Phe         | Phe Phe Phe | Phe         | Phe |
|    | (SEQ ID NO:5)   |             |             |             |     |

A charged residue Glu or Asp is added at position 1 to increase the charge surrounding the hydrophobic face of the Th. The hydrophobic face of the amphipathic helix is then maintained by hydrophobic residues at 2, 5, 8, 9, 10, 13 and 16. Positions at 2, 5, 8, 9, 10, and 13 are varied to provide a facade with the capability of binding to a wide range of MHC

restriction elements. The net effect of the SSAL feature is to enlarge the range of immune responsiveness of the artificial Th (WO 95/11998).

Other attempts have been made to design "idealized" artificial Th epitopes" incorporating all of the properties and features of known promiscuous Th epitopes. Several peptide immunogens comprising these artificial promiscuous Th epitopes, including those in the form of SSAL, have also been constructed. The artificial Th sites have been combined with peptide sequences taken from self-antigens and foreign antigens to provide enhanced antibody responses to site - specific targets (WO 95/11998; Alexander et al., *Immunity*, 1994, 1:751; Del Guerio et al., *Vaccine*, 1997, 15:441) that have been described as highly effective. Such peptide immunogens are preferred for providing effective and safe antibody responses, and for their immunopotency, arising from a broadly reactive responsiveness imparted by the idealized promiscuous Th sites described.

CL 0/C

#### SUMMARY OF THE INVENTION

20 The present invention provides an immunogenic peptide composition comprising a promiscuous artificial T helper cell epitope linked to a synthetic peptide B cell epitope or "target antigenic site". The immunogenic peptide comprise an artificial T helper cell (Th) epitopes and a target antigenic site containing B cell epitopes and, optionally, a general immune stimulator sequence. The presence of an artificial Th epitope in the immunogenic peptide impart thereto a capability to induce a strong T helper cell-mediated immune response with the production of a high level of antibodies directed against the "target antigenic site." The present invention further provides for the advantageous replacement of carrier proteins and pathogen-derived T helper cell sites in established peptide immunogens with artificial T helper cell epitopes designed specifically to improve their immunogenicity. The novel short peptide

35



immunogens with the artificial Th epitopes of the present invention elicit a high level of antibodies targeted to luteinizing hormone-releasing hormone (LHRH) useful for contraception, the control of hormone-dependent tumors, the prevention of boar taint, and immunocastration.

The artificial Th epitopes were developed empirically, mindful of the known rules for predicting promiscuous T cell epitopes. In the absence of a unifying theory explaining the mechanism of Th epitopes, these "predictive" rules serve merely as guidelines for designing effective artificial Th epitopes. The artificial Th epitopes of the present invention have been found to be useful when linked to target antigenic sites and optionally with a immunostimulatory sequence. The immunogenic peptides of the present invention may be represented by the formulae:

- 10 -

+i

 $(A)_n-(\text{Target antigenic site})-(B)_o-(\text{Th})_m-X$ 

or

+i

 $(A)_n-(B)_o-(\text{Th})_m-(B)_o-(\text{Target antigenic site})-X$ 

or

5 +i

 $(A)_n-(\text{Th})_m-(B)_o-(\text{Target antigenic site})-X$ 

or

+i

 $(\text{Target antigenic site})-(B)_o-(\text{Th})_m-(A)_n-X$ 

or

+i

 $(\text{Th})_m-(B)_o-(\text{Target antigenic site})-(A)_n-X$ 

p1

10 wherein: A is an amino acid or a general immunostimulatory sequence, e.g., the invasin domain (Inv) (SEQ ID NO:78) where n is more than one, the individual A's may be the same or different;

p1

15 B is selected from the group consisting of amino acids,  $-\text{NHCH}(X)\text{CH}_2\text{SCH}_2\text{CO}-$ ,  $-\text{NHCH}(X)\text{CH}_2\text{SCH}_2\text{CO}(\square\text{N})\text{Lys}-$ ,  $-\text{NHCH}(X)\text{CH}_2\text{S-succinimidyl}(\square\text{N})\text{Lys}-$ , and  $-\text{NHCH}(X)\text{CH}_2\text{S}-(\text{succinimidyl})-$ ;

p1

20 Th is an artificial helper T cell epitope selected from the group consisting of SEQ ID NOS:6-22, 31-35 and 105 and an analog or segment thereof;

p1

"Target antigenic site" is a desired B cell epitope, a peptide hapten, or an immunologically reactive analog thereof;

p1

25 X is an aminoacid  $\alpha\text{-COOH}$ ,  $-\text{CONH}_2$ ;  
n is from 1 to about 10;  
m is from 1 to about 4; and  
o is from 0 to about 10.

p

An example of a peptide hapten as a target antigenic site is LHRH (SEQ ID NO: 77).

30

The compositions of the present invention comprise peptides capable of evoking antibody responses in an immunized host to a desired target antigenic site. The target antigenic site may be derived from pathogenic organisms and normally immunosilent self-antigens and tumor-associated targets such as LHRH.

35

Accordingly, the compositions of the present invention are useful in many diverse medical and veterinary applications. These include vaccines to provide protective immunity from infectious disease, immunotherapies for the treatment of disorders resulting from the malfunction of normal physiological processes, immunotherapies for the treatment of cancer, and agents to desirably intervene in and modify normal physiological processes.

Some of the targets antigens which may be covalently linked to the Th epitopes of the present invention include: LHRH for contraception, the control of hormone dependent tumors and immunocastration; somatostatin for growth promotion in farm animals; IgE for treatment of allergy; the CD4 receptor of T helper cells for treatment and prevention of HIV infection and immune disorders; foot-and-mouth disease virus capsid protein as a vaccine for the prevention of foot-and-mouth disease; the CS antigen of Plasmodium for prevention of malaria; CETP for prevention and treatment of arteriosclerosis; and HIV virion epitopes for prevention and treatment of HIV infection.

CL C/C

#### DETAILED DESCRIPTION OF THE INVENTION

Idealized artificial Th epitopes have been provided. These are modeled on two known natural Th epitopes and SSAL peptide prototypes, disclosed in WO 95/11998. The SSALS incorporate combinatorial MHC molecule binding motifs (Meister et al., 1995) intended to elicit broad immune responses among the members of a genetically diverse population. The SSAL peptide prototypes were designed based on the Th epitopes of the measles virus and hepatitis B virus antigens, modified by introducing multiple MHC-binding motifs. The design of the other Th epitopes were modeled after other known Th epitopes by simplifying, adding, and/or modifying, multiple MHC-binding motifs to produce a series of novel artificial Th epitopes. The newly adapted promiscuous artificial Th sites were

incorporated into synthetic peptide immunogens bearing a variety of target antigenic sites. The resulting chimeric peptides were able to stimulate effective antibody responses to the target antigenic sites.

5           The prototype artificial helper T cell (Th) epitope shown in Table 1a as "SSAL1 Th1", a mixture of four peptides (SEQ ID NOS:2, 3, 4, 5) is an idealized Th epitope modeled from a promiscuous Th epitope of the F protein of measles virus (Partidos et al. 1991). The model Th epitope, shown in  
10 Table 1a as "MVF Th" (SEQ ID NO:1) corresponds to residues 288-302 of the measles virus F protein. MVF Th (SEQ ID NO:1) was modified to the SSAL1 Th1 prototype (SEQ ID NOS:2, 3, 4, 5) by adding a charged residue Glu/Asp at position 1 to increase the charge surrounding the hydrophobic face of the  
15 epitope; adding or retaining a charged residues or Gly at positions 4, 6, 12 and 14; and adding or retaining a charged residue or Gly at positions 7 and 11 in accordance with the "Rothbard Rule". The hydrophobic face of the Th epitope comprise residues at positions 2, 5, 8, 9, 10, 13 and 16.  
20 Hydrophobic residues commonly associated with promiscuous epitopes were substituted at these positions to provide the combinatorial Th SSAL epitopes, SSAL1 Th1 (SEQ ID NOS:2, 3, 4, 5). The hydrophobic residues conforming to the Rothbard sequence rule are shown in bold (Table 1a, SEQ ID NO:1).  
25 Positions in the sequence obeying the 1, 4, 5, 8 rule are underlined. Another significant feature of the prototype SSAL1 Th1 (SEQ ID NOS:2, 3, 4, 5) is that positions 1 and 4 is imperfectly repeated as a palindrome on either side of position 9, to mimic an MHC-binding motif. This "1, 4, 9"  
30 palindromic pattern of SSAL1 Th1 was further modified in SEQ ID NO:3 (Table 1a) to more closely reflect the sequence of the original MVF model Th (SEQ ID NOS:1). Also, the hydrophobicity of the SSAL1 Th1 prototype (SEQ ID NOS:2, 3, 4, 5) was modulated in SEQ ID NOS:6, 7, and 8 by the addition of  
35 methionine residues at variable positions 1, 12, and 14. Experimental data shows that SEQ ID NOS:6, 7, 8 coupled to a

target antigenic site enhanced the antibody response in the immunized animals to the target antigenic site.

SEQ ID NOS:6, 7, 8 was simplified to SEQ ID NOS:6, 9, 10 and 11 (Table 1a) to provide further immunogenic SSAL Th epitopes. SEQ ID NOS:6, 7, 8 was further simplified to SEQ ID NOS:6, 12-14 (Table 1a) to provide a series of single-sequence epitopes. SSAL Th SEQ ID NOS:4, 9, 10 and 11 and the single sequence Th epitopes SEQ ID NOS:6, 12-14, coupled to target antigenic sites also provided enhanced immunogenicity

It was found that the immunogenicity of SEQ ID NOS:6, 7, 8 may be improved by extending the N terminus with a non-polar and a polar uncharged amino acid, e.g., Ile and Ser, and extending the C terminus by a charged and hydrophobic amino acid, e.g., Lys and Phe. This is shown in Table 1a as SEQ ID NO:15, 16 and 17 from which simplified SSAL Th epitopes SEQ ID NOS:15 and 18, 105 and 19 were derived. Peptide immunogens comprising a target antigenic site and a Th epitope selected from SEQ ID NOS:15-17, 15 and 18, 105 and 19, and 123 and 124 displayed enhanced immunogenicity. Single-sequence peptides such as SEQ ID NOS:15, 20-22 were also synthesized and tested for immunogenicity in animals. These were also found to be effective Th epitopes.

The SSAL artificial helper epitope shown in Table 1b as "SSAL2 Th2" (SEQ ID NOS:26-30) was modeled after a promiscuous epitope from the hepatitis B virus surface antigen SEQ ID NO:23 corresponding to residues 19-33 of the hepatitis B surface antigen (HBsAg) (Greenstein et al. 1992). The pathogen-derived model Th, was modified to SEQ ID NO:24 by adding three Lysines to improve solubility in water; the C-terminal Asp was deleted in SEQ ID NO:25 to facilitate the synthesis of chimeric peptides wherein Gly-Gly was introduced as spacers. The SSAL2 Th2 (SEQ ID NOS:26-30) was further modified from SEQ ID NO:24 by varying the positively charged residues therein at positions 1, 2, 3 and 5 to vary the charge surrounding the hydrophobic face of the helical structure. A charged amino acid at variable position 3 also contributed a

required residue to generate the idealized Th epitope, SSAL2 Th2 (SEQ ID NOS:26-30), which obeyed the 1, 4, 5, 8 rule (underlined residues). The hydrophobic face of the amphipathic helix consists of hydrophobic residues at

5 positions 4, 6, 7, 10, 11, 13, 15 and 17 of SEQ ID NOS:26-30.

The Rothbard sequence residues are shown in bold for prototype SSAL2 Th2 (SEQ ID NOS:26-30).

SEQ ID NOS:31-35 were simplified from the idealized SSAL2 Th2 prototype (SEQ ID NOS:26-30) as described above.

10 For example, variable hydrophobic residues were replaced with single amino acids, such as Ile or Met (SEQ ID NOS:31-35).

The hydrophobic Phe in position 4 was incorporated as a feature of SEQ ID NO:34 while deleting the three lysines. The deletion of the C-terminal Asp was incorporated as a feature  
15 of SEQ ID NOS:32, 34, and 35. Further modifications included the substitution of the C-termini by a common MHC-binding motif AxTxIL (Meister et al, 1995).

Each of the novel artificial Th epitopes, SEQ ID NOS:6, 12-19, 105, 123, 124 20-22 and 31-35 were coupled to a  
20 variety of target antigenic sites to provide peptide immunogens. The target antigenic sites include the peptide hormones, LHRH and somatostatin, B cell epitopes from immunoglobulin IgE, the T cell CD4 receptor, the VP1 capsid protein of foot-and-mouth disease virus; the CS antigen of  
25 Plasmodium falciparum; and cholesteryl ester transport protein (CETP); and B cell epitopes from HIV. The results show that effective anti-target site antibodies cross-reactive with a diverse group of self-antigens and foreign antigens were produced. Most important, the antibody responses were  
30 directed to the target antigenic sites and not to the novel Th epitopes. The results for the novel peptide immunogens for LHRH are shown in Tables 2 and 3. The immunogenicity results also show that the antibodies produced were effective against LHRH but not against the Th epitopes themselves. It is to be  
35 emphasized that LHRH is a target antigenic site devoid of T cell epitopes (Sad et al., *Immunology*, 1992; 76: 599-603 and

US 5,759,551). Thus, the novel artificial Th epitopes of the present invention represent a new class of promiscuous T helper epitopes.

The artificial Th epitopes of the present invention are contiguous sequences of amino acids (natural or non-natural amino acids) that comprise a class II MHC molecule binding site. They are sufficient to enhance or stimulate an antibody response to the target antigenic site. Since a Th epitope can consist of continuous or discontinuous amino acid segments, not every amino acid of the Th epitope is necessarily involved with MHC recognition. The Th epitopes of the invention further include immunologically functional homologues. Functional Th homologues include immune-enhancing homologues, crossreactive homologues and segments of any of these Th epitopes. Functional Th homologues further include conservative substitutions, additions, deletions and insertions of from one to about 10 amino acid residues and provide the Th-stimulating function of the Th epitope.

The promiscuous Th epitopes of the invention are covalently linked to the N- or C- terminus of the target antigenic site, to produce chimeric Th/B cell site peptide immunogens. The term "peptide immunogen" as used herein refers to molecules which comprise Th epitopes covalently linked to a target antigenic site, whether through conventional peptide bonds so as to form a single larger peptide, or through other forms of covalent linkage, such as a thioester. Accordingly, the Th epitopes (e.g., SEQ ID NOS:6, 12-19, 105, 123, 124, 20-22 and 31-35) are covalently attached to the target antigenic site (e.g., SEQ ID NO:77) either via chemical coupling or via direct synthesis. The Th epitopes may be attached directly to the target site or through a spacer, e.g., Gly-Gly or ( $\square$ -N)Lys. In addition to physically separating the Th epitope from the B cell epitope (e.g., SEQ ID NOS:41-64, 71-76, 84-90, 92-94, 96-102, 103, 104, 106, 126-129, and 136-153), the spacer may disrupt any artifactual secondary structures created by the linking of the Th epitope

or its functional homologue with the target antigenic site and thereby eliminate any interference with the Th and/or B cell responses. A flexible hinge spacer that enhances separation of the Th and IgE domains can also be useful. Flexible hinge sequences are often proline rich. One particularly useful flexible hinge is provided by the sequence Pro-Pro-Xaa-Pro-Xaa-Pro (SEQ ID NO:79) modeled from the flexible hinge region found in immunoglobulin heavy chains. Xaa therein is any amino acid, preferably aspartic acid. The conformational separation provided by the spacer (See SEQ ID NOS:80 and 82) permits more efficient interactions between the presented peptide immunogen and the appropriate Th cells and B cells. Thus the immune responses to the Th epitope is enhanced to provide improved immune reactivity.


The peptide conjugate immunogens of the invention optionally may also comprise a general immunostimulatory peptide sequence. For example, a domain of an invasin protein (Inv) from the bacteria *Yersinia* spp (Brett et al., *Eur J Immunol*, 1993, 23: 1608-1614). This immune stimulatory property results from the capability of this invasin domain to interact with the  $\beta 1$  integrin molecules present on T cells, particularly activated immune or memory T cells. A preferred embodiment of the invasin domain (Inv) for linkage to a promiscuous Th epitope has been previously described in US 5,759,551 and is incorporated herein by reference. The said Inv domain has the sequence:

Thr-Ala-Lys-Ser-Lys-Lys-Phe-Pro-Ser-Tyr-Thr-Ala-Thr-Tyr-Gln-Phe  
(SEQ ID NO:78)

or is an immune stimulatory homologue thereof from the corresponding region in another *Yersinia* species invasin protein. Such homologues thus may contain substitutions, deletions or insertions of amino acid residues to accommodate strain to strain variation, provided that the homologues retain immune stimulatory properties. The general immunostimulatory sequence may optionally be linked to the Th epitope with a spacer sequence.



The peptide conjugates of this invention, i.e., peptide immunogens which comprise the described artificial Th epitopes, can be represented by the formulas:



*P1*  
*P5* wherein: A is optional and is an amino acid or a general  
 15 immunostimulatory sequence, where  $n > 1$ , each A may be the same or different;

*P1* B is selected from the group consisting of amino  
 acids,  $-\text{NHCH}(X)\text{CH}_2\text{SCH}_2\text{CO}-$ ,  $-\text{NHCH}(X)\text{CH}_2\text{SCH}_2\text{CO}(\square-\text{N})\text{Lys}-$ ,  $-\text{NHCH}(X)\text{CH}_2\text{S-succinimidyl}(\square-\text{N})\text{Lys}-$ , and  $-\text{NHCH}(X)\text{CH}_2\text{S}-$   
 20 (succinimidyl)-;

*P1* Th is an artificial helper T cell epitope (SEQ ID  
 NOS:6, 12-19, 105, 20-22 and 31-35) or an immune enhancing  
 homologue or segment thereof;

*P1* "Target antigenic site" is a desired B cell epitope  
 25 or peptide hapten, or an analog thereof);

*P1* X is an amino acid  $\alpha\text{-COOH}$  OR  $-\text{CONH}_2$ ;

n is from 1 to about 10;

m is from 1 to about 4; and

o is from 0 to about 10.

*P1*  
 30 The peptide immunogens of the present invention  
 comprises from about 25 to about 100 amino acid residues,  
 preferably from about 25 to about 80 amino acid residues.

When A is an amino acid, it can be any non-naturally  
 occurring or any naturally occurring amino acid. Non-  
 35 naturally occurring amino acids include, but are not limited

gto, D-amino acids,  $\beta$ -alanine, ornithine, norleucine, norvaline, hydroxyproline, thyroxine,  $\gamma$ -amino butyric acid, homoserine, citrulline and the like. Naturally-occurring amino acids include alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine. Moreover, when n is greater than one, and two or more of the A groups are amino acids, then each amino acid may be independently the same or different.

When A is an invasin domain sequence, it is preferably an immune stimulatory epitope from the invasin protein of an *Yersinia* species described here as SEQ ID NO:77.

In one embodiment where n is 3, each A is in turn an invasin sequence (Inv), glycine and glycine.

B is optional and is a spacer comprising one or more naturally occurring or non-naturally occurring amino acids. In (B)<sub>0</sub>, where 0>1, each B may be same or different. B may be Gly-Gly or Pro-Pro-Xaa-Pro-Xaa-Pro (SEQ ID NO:79) or  $\square$ NLys or -NHCH(X)CH<sub>2</sub>SCH<sub>2</sub>CO-, -NHCH(X)CH<sub>2</sub>SCH<sub>2</sub>CO( $\square$ NLys)-, -NHCH(X)CH<sub>2</sub>S-succinimidyl- $\square$ NLys-, and -NHCH(X)CH<sub>2</sub>S-(succinimidyl)-.

Th is a promiscuous T helper cell epitope selected from the group SEQ ID NOS:6, 12-19, 105, 123, 124, 20-22 and 31-35 and homologues thereof.

The peptide immunogens of this invention, may be made by chemical methods well known to the ordinarily skilled artisan. See, for example, Fields et al., Chapter 3 in *Synthetic Peptides: A User's Guide*, ed. Grant, W.H. Freeman & Co., New York, NY, 1992, p.77. The peptides may be synthesized using the automated Merrifield solid phase peptide synthesis with either t-Boc or Fmoc to protect the  $\alpha$ -NH<sub>2</sub> or side chain amino acids. Equipment for peptide synthesis are available commercially. One example is an Applied Biosystems Peptide Synthesizer Model 430A or 431.

After complete assembly of the desired peptide

immunogen, the resin is treated according to standard procedures to cleave the peptide from the resin and de-block the functional groups on the amino acid side chains. The free peptide is purified by HPLC and characterized biochemically, for example, by amino acid analysis, by sequencing, or by mass spectrometry. Methods of peptide purification and characterization are well known to one of ordinary skill in the art.

Other chemical means to generate peptide immunogens comprising the Th epitopes of the invention include the ligation of haloacetylated and cysteinylated peptides through the formation of a "thioether" linkage. For example, a cysteine can be added to the C terminus of a Th-containing peptide and the thiol group of cysteine may be used to form a covalent bond to an electrophilic group such as an N-chloroacetyl-modified or a maleimide-derivatized  $\square$ - or  $\square$ -NH<sub>2</sub> group of a lysine residue, which is in turn attached to the N-terminus of a target antigenic site peptide. In this manner, Th epitope/B cell site conjugates may be obtained.

The subject immunogen may also be polymerized. Polymerization can be accomplished for example by reaction between glutaraldehyde and the -NH<sub>2</sub> groups of the lysine residues using routine methodology. By another method, the linear Th/ B cell site immunogen can be polymerized or co-polymerized by utilization of an additional cysteine added to the N-terminus of the linear constructs. The thiol group of the N-terminal cysteine can be used for the formation of a "thioether" bond with haloacetyl-modified amino acid or a maleimide-derivatized  $\square$ - or  $\square$ -NH<sub>2</sub> group of a lysine residue that is attached to the N-terminus of a branched poly-lysyl core molecule (e.g., K<sub>2</sub>K, K<sub>4</sub>K<sub>2</sub>K or K<sub>8</sub>K<sub>4</sub>K<sub>2</sub>K). The subject immunogen may also be polymerized as a branched structure through synthesis of the desired peptide construct directly onto a branched poly-lysyl core resin (Wang, et al., Science, 1991; 254:285-288).

The longer synthetic peptide conjugates may

alternatively be synthesized by well known nucleic acid cloning techniques. Any standard manual on molecular cloning technology provides detailed protocols to produce peptides comprising the Th epitopes of the invention by expression of recombinant DNA and RNA. To construct a gene expressing a Th/target antigenic site peptide of this invention (e.g., SEQ ID NOS:36-64, 106, 71-76 and 80-82), the amino acid sequence is reverse translated into a nucleic acid sequence, preferably using optimized codons for the organism in which the gene will be expressed. Next, a gene encoding the peptide is made, typically by synthesizing overlapping oligonucleotides which encode the peptide and necessary regulatory elements. The synthetic gene is assembled and inserted into the desired expression vector. The synthetic nucleic acid sequences encompassed by this invention include those which encode the Th epitopes of the invention and peptides comprising those Th epitopes, the immunologically functional homologues thereof, and nucleic acid constructs characterized by changes in the non-coding sequences that do not alter the immunogenic properties of the peptide or Th epitope encoded thereby. The synthetic gene is inserted into a suitable cloning vector and recombinants are obtained and characterized. The Th epitopes and peptides comprising the Th epitopes are then expressed under conditions appropriate for the selected expression system and host. The Th epitope or peptide is purified and characterized by standard methods.

Peptide immunogens of the invention may be used alone or in combination to elicit antibody responses to Luteinizing Hormone Releasing Hormone. Luteinizing Hormone Releasing Hormone (LHRH) or Gonadotropin-releasing hormone (GnRH) is a master hormone for the regulation of sexual reproduction in both males and females. LHRH regulates the release of LH and FSH which in turn control spermatogenesis, ovulation and estrus, sexual development. LHRH ultimately controls the secretion of the male hormones androgen and testosterone, and the secretion of the female hormones,

estrogen and progesterone which themselves are essential for fertility in males and females, respectively. (*Basic and Clinical Endocrinology*, eds. FS Greenspan and JD Baxter, Appleton & Lange:Norwalk CT. 1994).

5 Active immunization against LHRH has long been known to exert multiple effects in males including decreased serum and pituitary LH and FSH, reduced serum testosterone, suppression of spermatogenesis and reversible atrophy of the gonads and accessory sex organs. (See, for example, Fraser et  
10 al., *J. Endocrinol.*, 1974; 63:399-405; Giri et al., *Exp. Molec. Pathol.*, 1991; 54:255-264; Ladd et al., *J. Reprod. Immunol.*, 1989; 15:85-101; and references cited therein). Immunization against LHRH has been proven useful as a contraceptive in males and has potential as a treatment for  
15 prostate cancer (Thau, *Scand J Immunol*, 1992; 36 Suppl 11:127-130; and US 5,759,551).

Immune intervention on the hypothalamo-pituitary gonadal axis by active immunization against LHRH can also be used to inhibit sexual hormones in females. Since LHRH  
20 regulates the production of FSH by the anterior pituitary which in turn regulates the production of estrogen by the ovaries, blocking the action of LHRH is a therapy for sexual hormone-dependent diseases in women. For example, the ectopic development and maintenance of endometrial tissues outside the  
25 uterine musculature is mediated by estrogen. Therefore, blocking the action of LHRH is useful as a treatment for endometriosis. Furthermore, by analogy to prostate cancer, estrogen-driven tumors of the breast should also be responsive to LHRH immunotherapy. Indeed, an anti-LHRH inducing vaccine  
30 has been shown to effectively reduce serum levels of LH and FSH in women, an illustration of the potential of this method to effect contraception and treatment of hormone-dependent disorders (Gual et al., *Fertility and Sterility*, 1997; 67: 404-407).

35 In addition to providing treatment for a number of

important diseases and reversible infertility in both men and women, LHRH-based immunotherapy provides a means for reversible contraception in male and female animals (e.g. dogs, cats, horses and rabbits) as well as mitigating undesirable androgen-driven behavior such as heat, territorial marking and aggression.

Lastly, immunological castration (e.g., antibody-based inhibition of LHRH action) has application in the livestock industry. Meat from male animals is not processed into prime cuts because of the presence of an offensive aroma and taste, known as boar taint. Boar taint is conventionally eliminated by mechanical castration; however, castration of male food animals is no longer considered humane. Moreover, mechanical castration results in poorer growth performance and lesions in body part, also referred to as carcass traits, in comparison to non-castrated males. Whereas, the growth performance and carcass traits of immunocastrated animals are less affected than those of castrated animals (Bonneau et al., *J Anim Sci*, 1994; 72: 14-20 and US 5,573,767). Therefore, immunological castration is preferable to mechanical castration.

LHRH (or GnRH) is a self-molecule that must be linked to a Th component in order to generate anti-LHRH antibodies (Sad et al., *Immunology*, 1992; 76: 599-603). Several such immunogenic forms of LHRH have been tested. For example, LHRH immunogens have been produced by conjugation to carrier proteins or linked by peptide synthesis to potent Th sites derived from pathogenic organisms (WO 94/07530, US 5,759,551, Sad et al., 1992). Improved LHRH peptide immunogens comprising LHRH and artificial Th epitopes are exemplified in EXAMPLES 1-3.

This invention also provides for compositions comprising pharmaceutically acceptable delivery systems for the administration of the peptide immunogens. The compositions comprise an immunologically effective amount of one or more of the peptide immunogens of this invention. When

so formulated, the compositions of the present invention comprising LHRH or a homologue thereof as target antigenic site, are used for treatment of prostate cancer, prevention of boar taint, immunocastration of animals, the treatment of endometriosis, breast cancer and other gynecological cancers affected by the gonadal steroid hormones, and for contraception in males and females. The utility for peptides of the invention having target antigenic sites other than LHRH will vary in accordance with the specificity of the target antigenic site.

The peptide immunogens of the invention can be formulated as immunogenic compositions using adjuvants, emulsifiers, pharmaceutically-acceptable carriers or other ingredients routinely provided in vaccine compositions. Adjuvants or emulsifiers that can be used in this invention include alum, incomplete Freund's adjuvant (IFA), liposyn, saponin, squalene, L121, emulsigen, monophosphoryl lipid A (MPL), dimethyldioctadecylammonium bromide (DDA), QS21, and ISA 720, ISA 51, ISA 35 or ISA 206 as well as the other efficacious adjuvants and emulsifiers. Such formulations are readily determined by one of ordinary skill in the art and also include formulations for immediate release and/or for sustained release. The present vaccines can be administered by any convenient route including subcutaneous, oral, intramuscular, intraperitoneal, or other parenteral or enteral route. Similarly the immunogens can be administered in a single dose or multiple doses. Immunization schedules are readily determined by the ordinarily skilled artisan.

The composition of the instant invention contains an effective amount of one or more of the peptide immunogens of the present invention and a pharmaceutically acceptable carrier. Such a composition in a suitable dosage unit form generally contains about 0.5µg to about 1 mg of the peptide immunogen per kg body weight. When delivered in multiple doses, it may be conveniently divided into an appropriate amount per dose. For example, the dose, e.g. 0.2-2.5mg;

preferably 1 mg, may be administered by injection, preferably intramuscularly. This may be followed by repeat (booster) doses. Dosage will depend on the age, weight and general health of the subject as is well known in the vaccine and therapeutic arts.

Vaccines comprising mixtures of the subject peptide immunogens, particularly mixtures comprising Th sites derived from both MVF Th, i.e., SEQ ID NOS:6, 12-19, 105, 123, 124, 20-22, and HBsAg Th, i.e., SEQ ID NOS:31-35, may provide enhanced immunoefficacy in a broader population and thus provide an improved immune response to LHRH or other target antigenic site.

The immune response to Th/LHRH peptide conjugates or other Th/target antigenic site conjugates can be improved by delivery through entrapment in or on biodegradable microparticles of the type described by O'Hagan et al. (Vaccine, 1991; 9:768). The immunogens can be encapsulated with or without an adjuvant, and such microparticles can carry an immune stimulatory adjuvant. The microparticles can also be coadministered with the peptide immunogens to potentiate immune responses

As a specific example, the invention provides a method for inducing anti-LHRH antibody by administering pharmaceutical compositions comprising Th/LHRH peptide immunogens to a mammal for a time and under conditions to produce an infertile state in the mammal. As used herein an infertile state is that state which prevents conception. Infertility can be measured by methods known in the art, e.g. evaluation of spermatogenesis or ovulation, as well as by statistical modeling of experimental animal data. Other indicators of infertility in males includes reduction of serum testosterone to castration levels and involution of the testes. The appropriate dose of the composition is about 0.5µg to about 1mg of each peptide per kg body weight. This dosage may conveniently be divided into appropriate amounts



per dose when delivered in multiple doses.

Similarly, the LHRH embodiments of this invention relate to a method for treating androgen-dependent carcinoma by administering the subject peptide compositions to the mammal for a time and under conditions to prevent further growth of the carcinoma. The appropriate unit dose is about 0.5 $\mu$ g to about 1mg of each peptide per kg body weight. This is conveniently divided into the appropriate amounts per application when administered in multiple doses.

Further, the LHRH embodiments relate to a method for improving the organoleptic qualities and tenderness of the meat from male domestic animals while maintaining the advantageous growth performance of intact males. The androgenic steroid hormones of intact males are responsible for fast growth but their presence is accompanied by non-androgenic steroids (e.g., 5 $\alpha$ -androstenone) and skatole (a product of the microbial metabolism of tryptophan) which impart unpleasant taste and aroma to the meat. This condition, known as boar taint in the case of swine, detracts from the quality of the meat. However, by the active immunization of young males with compositions comprising LHRH peptides of the invention, on a schedule that effects immunocastration in the weeks just prior to slaughter, many of the growth advantages of non-castrated males may be retained while providing meat with improved flavor and tenderness.

The efficacy of the peptide composition of the present invention comprising the target antigenic site, LHRH, can be tested by the procedure described in the Examples 1-3.

Other target antigenic sites which have also been used in peptide immunogens of the present invention are described in Examples 4-9. Peptide immunogen compositions are useful for inducing immune responses in mammals against specific target antigens and provide for prevention or treatment of disease, or intervene to usefully modify normal physiological conditions.

DE CL U/K  
CL U/L

EXAMPLE 1IMMUNIZATION OF RATS WITH PEPTIDE  
IMMUNOGENS CONTAINING LHRH

5                   Peptides listed in Tables 2a and 2b were synthesized and tested as described below.

10                   A. Peptide synthesis. The peptides listed in Tables 2a and 2b were synthesized individually by the Merrifield solid-phase synthesis technique on Applied Biosystems automated peptide synthesizers (Models 430, 431 and 433A) using Fmoc chemistry. Preparation of peptide constructs comprising structured synthetic antigen libraries (SSALs), e.g., the artificial Th site designated SEQ ID NO:6-8, was accomplished by providing a mixture of the desired amino acids selected for a given position. After complete assembly of the desired peptide or combinatorial peptides, the resin was treated according to standard procedure using trifluoroacetic acid to cleave the peptide from the resin and deblock the protecting groups on the amino acid side chains.

15                   The cleaved, extracted and washed peptides were purified by HPLC and characterized by mass spectrometry and reverse phase HPLC.

20                   Peptides were synthesized to have the LHRH target antigenic peptide (SEQ ID NO:77) in tandem with each of the designed Th epitopes as listed in Tables 2a and 2b. The Th epitopes were those shown in Tables 1a and 1b (SEQ ID NOS:6, 12-19, 105, 20-22 and 31-35). For purposes of comparison, prior art peptide immunogens comprising model Th sites (SEQ ID NOS:36 and 65), and prototype Th sites (SEQ ID NOS:37-40 and 66-70) and a peptide/carrier protein conjugate, KLH-LHRH (Table 2b) were also synthesized and tested. The Th/LHRH and Inv/Th/LHRH peptide constructs were synthesized with gly-gly as a spacer between the target antigenic site and the Th epitope, and with or without gly-gly as a spacer between the Th epitope and the Inv immunostimulatory sequence. In

addition, SEQ ID NOS:80-82 were synthesized with SEQ ID NO:79 as a spacer between the Th site and the target antigenic site.

The results for peptide immunogens SEQ ID NOS:80-82 are not yet available.

5            B. Protocols for immunization.    The LHRH peptide immunogens shown in Tables 2a and 2b were evaluated on groups of 5 to 10 rats as specified by the experimental immunization protocol outlined below and by serological assays for determination of immunogenicity on serum samples:

10 *P1* Animals: Sprague-Dawley rats, male  
Group Size: 5-10 rats/group  
Immunogen: individual peptide immunogen  
Dose: amount in µg as specified, in 0.5mL  
Adjuvants: *P2* (1) Freund's Incomplete Adjuvant (IFA);  
or  
15 *P2* (2) Alum (Aluminum hydroxide);  
One adjuvant per immunogen per group

p/ Dose Schedule: 0, 3, and 6 weeks or 0, 3 weeks as specified

20 *PI* Route: intramuscular  
*P* Blood was collected and processed into serum, and stored prior to ELISA and radioimmunoassay (RIA) for determination of serum testosterone values.

C. Method for determination of immunogenicity.

25 Antibody activities were determined by ELISA (enzyme-linked immunosorbent assays) using 96-well flat bottom microtiter plates which were coated with the LHRH peptide (SEQ ID NO:77) as immunosorbent. Aliquots (100 $\mu$ L) of the peptide immunogen solution at a concentration of 5 $\mu$ g/mL were incubated for 1  
30 hour at 37°C. The plates were blocked by another incubation at 37°C for 1 hour with a 3% gelatin/PBS solution. The blocked plates were then dried and used for the assay. Aliquots (100 $\mu$ L) of the test immune sera, starting with a 1:100 dilution in a sample dilution buffer and ten-fold serial  
35 dilutions thereafter, were added to the peptide coated plates.

The plates were incubated for 1 hour at 37°C.

The plates were washed six times with 0.05% TWEEN® in PBS. 100µL of horseradish peroxidase labeled goat-anti-rat IgG antibody was added at appropriate dilutions in conjugate dilution buffer (Phosphate buffer containing 0.5M NaCl, and normal goat serum). The plates were incubated for 1 hour at 37°C before being washed as above. Aliquots (100µL) of o-phenylenediamine substrate solution were then added. The color was allowed to develop for 5-15 minutes before the enzymatic color reaction was stopped by the addition of 50µL 2N H<sub>2</sub>SO<sub>4</sub>. The A<sub>492nm</sub> of the contents of each well was read in a plate reader. ELISA titers were calculated based on linear regression analysis of the absorbances, with cutoff A<sub>492nm</sub> set at 0.5. This cutoff value was rigorous as the values for diluted normal control samples run with each assay were less than 0.15.

D. Determination of immunogen efficacy. Immunogens were evaluated for efficacy by RIA for serum testosterone values. Serum testosterone levels were measured using an RIA kit from Diagnostic Products (Los Angeles, CA) according to manufacturer's instructions. The lower detection limit for testosterone ranged from 0.01 to 0.03nmol/L. Each sample was analyzed in duplicate. Serum samples were scored as being at castration level when the testosterone level was below limits of detection and as "near castration" at <0.1nmol/L. Results were verified by comparison to testosterone levels in serum from mechanically castrated rats.

E. Results. Results from serum samples collected at weeks 10 or 12 are presented in Tables 2a and 2b. (The peptides of the Tables are ordered by derivation of their Th epitopes, as was done in Tables 1a and 1b.) ELISA data (not shown) demonstrated that immunization by all the listed immunogens resulted in antibody responses in all animals. The efficacy of the anti-peptide antibody responses, consequential to the cross-reactivity to natural LHRH, was established by

determining serum testosterone levels. Those results are summarized in the right columns of Tables 2a and 2b as numbers of animals having castration level serum testosterone per total animals in the group.

5           The results show that the peptides of the invention, whether with a strong adjuvant IFA and administered 3 times at high dose, or with a weak adjuvant Alum and administered twice at low dose were effective in producing immunocastration. The immunogenicity of the Th sites SEQ ID NOS:6, 9 and 15 were  
10 improved by the addition of the Inv domain sequence. See comparisons between SEQ ID NOS:41, 44 and 45, 46 and SEQ ID NOS:53 and 60. Although, the addition of the Inv domain sequence did not always result in improvement in  
15 immunogenicity, e.g., compare SEQ ID NOS:51 and 52, SEQ ID NOS:61 and 62, and, SEQ ID NOS:74 and 75. Two peptides of the invention (SEQ ID NOS:50 and 76) were tested only at low dose with the weak adjuvant and failed to cause immunocastration, but the results with other peptides, e.g., SEQ ID NO:73, indicate that they would have been effective at a higher dose  
20 with a strong adjuvant. Many of the LHRH peptide immunogens of the present invention were significantly more effective at inducing immunocastration than the KLH/LHRH peptide carrier protein conjugate or the peptide immunogens having HBsAg Th (SEQ ID Nos:65 and 66-70). See Table 2b.

25           Also, the peptide immunogens of the present invention were more easily synthesized than the peptide/carrier conjugate protein or the peptide immunogens having the more complex prototype Th epitopes of the prior art (SEQ ID NOS:2-5 or 26-30). Yet, equivalent or improved  
30 immunogenicity with fewer and lower doses were obtained with the peptide immunogens comprising the artificial Th epitopes of the present invention.

          A serological analysis of the antibody responses of rats that had received the LHRH peptides of the invention  
35 demonstrated that the antibody responses to the peptides was specifically directed to the target antigenic site and not to

the novel artificial Th sites. This is a distinct advantage of these peptide immunogens over conventional peptide/carrier protein conjugates. Serum samples from rats that had been immunized with the peptide immunogens shown in Table 3, with 25µg doses on Alum at 0 and 3 weeks, were compared for reactivities to the LHRH target site and to the Th epitope by ELISAs using the LHRH peptide (SEQ ID NO:77) and the appropriate Th epitope (SEQ ID NO:15 and 18, 31, or 34) as solid-phase substrates in peptide-based ELISAs. Results for these ELISAs are presented in Table 3 which show that despite high titer responsiveness to the LHRH moiety of the Th/LHRH peptide conjugates, reactivities for the artificial Th sites were at background levels.

CL U/C

CL U/L

EXAMPLE 2LHRH PEPTIDE MIXTURE FOR INDUCTION OF BROADER  
IMMUNOCASTRATION IN RATS

5 Establishing the relative efficacies of the various  
artificial Th epitope/LHRH constructs as shown above in  
Example 1 permitted selection of the most effective ones for  
assembly into a peptide mixture of enhanced immunogenicity. A  
mixture of Th/LHRH peptide immunogens is more efficacious than  
10 any individual peptide within the mixture (US 5,795,551).  
Moreover, a mixture of individual constructs carrying  
promiscuous Th epitopes derived from MVF Th (SEQ ID NO:1) and  
HBsAg Th (SEQ ID NOS:23-25) provide broader response in a  
genetically diverse population than would a peptide  
15 composition having Th epitopes derived from only one  
promiscuous Th epitope. Therefore, a peptide composition  
comprising a mixture of peptides of the invention derived from  
MVF Th and HBSAg Th was assembled and the efficacy of the  
mixture was tested and compared to compositions comprising the  
20 individual peptides of the mixture.

Groups of 6 or 8 male rats were immunized with 25µg  
doses (total dose) of the peptide compositions indicated in  
Table 4. The peptides in the mixture were combined in  
equimolar proportions. The peptides were formulated with 0.4%  
25 Alum and administered intramuscularly on weeks 0 and 3. Serum  
testosterone levels were followed for 22 weeks and the results  
were scored as number of animals with castration level of  
testosterone per total number of animals in the group. These  
results are presented in Table 4. They demonstrated that the  
30 low doses of peptide compositions, given with a relatively  
ineffective adjuvant, achieved castration levels of  
testosterone by week 5, and that this response was maintained  
through week 22. Moreover, the peptide mixture performed  
significantly better than one of the peptide compositions  
35 comprising an individual peptide. It can be assumed that the

mixture would have shown improved immunogenicity over the other individual peptide composition had the numbers of experimental animals been larger and more representative of a true population.

5 CL u/c

CL u/L

### EXAMPLE 3

#### LHRH PEPTIDE MIXTURE AND FORMULATIONS FOR THE IMUNOCASTRATION OF SWINE

10 A group test animals have been shown to be more broadly responsive to a mixture of peptide immunogens with different Th epitopes than to a composition containing a single peptide immunogen. However, for the prevention of boar taint in swine, it is necessary that the immunopotent LHRH  
15 peptide immunogens be sufficiently potent to elicit the desired response in most animals while being acceptable for use in food animals. It is important that there is no immediate effect adverse to the growth rate and that no residue of the peptide immunogen or the adjuvant is left in  
20 the meat or cause lesions in the marketable parts of the carcass.

In order to evaluate the useful immunogenicity of a mixture of inventive LHRH peptides, the mixture was administered to swine in three formulations either in 0.4%  
25 Alum, IFA, or ISA 206/DDA. ISA 206/DDA is an oil/water emulsion in which Dimethyldioctadecylammonium bromide (DDA) is dispersed into MONTANIDE® ISA 206 at 30mg/mL (MONTANIDE® ISA 206 is an oily metabolizable solution supplied by SEPPIC Inc. of Fairfield, NJ). The oil suspension is then emulsified at a  
30 1:1 volume ratio into an aqueous peptide solution which has been adjusted for peptide concentration so as to provide the desired dose of peptide in 0.5mL of the final preparation.

The immunization protocol was as follows:

pl Animals: Yorkshire Hampshire Cross Swine, males,



- 3-4 weeks of age non-castrated
- pl Group Size: 2-3 animals/group
- L Immunogen: Equimolar mixture of SEQ ID NOS:57-58, 71 and 75
- 5 pl Dose: 400µg of peptide(s) in 0.5mL
- L Adjuvants: P2 (1) 0.4% Alum,  
(2) IFA,  
(3) ISA 206/DDA
- pl Schedule: 0, 4, and 13 weeks or 0, 4 weeks
- 10 L Route: Intramuscular

P The efficacy of the peptide immunogen formulations was monitored by assaying the swine serum samples collected throughout the course of the study. ~~the results are graphically presented in Figs 1-3.~~ The assays included an RIA for the determination of the presence of antibodies cross-reactive to native LHRH in solution as described below, and an RIA for testosterone as described in EXAMPLE 1. Further, the average testes cross sectional area was determined by palpitation with a caliper.

20 Antisera for the anti-LHRH RIA were diluted 1:100 in 1% bovine serum albumin (BSA), pH 7.4. An equal volume of diluted sera was added to 100µL of [<sup>125</sup>I]-LHRH (New England Nuclear Company, Boston, MA) diluted in 1% BSA to contain approximately 15,000cpm for 5.25pg LHRH. The solution was

25 incubated overnight at room temperature and antibody-bound LHRH was precipitated with 400µL of 25% polyethylene glycol (MW 8,000) in 0.01M phosphate-buffered saline (PBS), pH 7.6, and 200µL of 5mg/mL bovine gamma globulin in PBS. Anti-LHRH antibody concentrations are expressed as nmol iodinated LHRH

30 bound per liter of serum (Ladd et al., 1988, *Am J Reprod Immunol*, 17:121-127).

~~Results are depicted graphically in Figs 1-3 for the three assays. The intervals at which the immunogens were administered are shown by arrows at the bottom of the graphs.~~

35 Determinations for the ~~individual~~ experimental animals in

each figure are represented by the solid circles, triangles, and squares. The swine responded immunologically to all three formulations, as shown by the presence of anti-LHRH antibody and the concomitant suppression of testosterone.

5 The alum preparation (~~Fig. 1~~) was least effective producing a lower level of antibody responses. One animal of this group did not achieve the castration level of testosterone until week 11 and both animals in this group did not manifest complete involution of the testes. The animals  
10 of the alum group did not receive immunizations at week 13, and the effects of the treatment were reversed.

E4 The animals of the IFA group (~~Fig. 2~~) displayed higher levels of antibody responses, with two of the three reaching and holding a castration level of testosterone by  
15 week 6. However, upon administration of a booster dose at week 13, the lowest responding swine of the three failed to respond and reverted to a normal level of testosterone and to non-involuted testes. The two responsive animals of this group achieved complete involution of the testes by week 23.

E5 20 Both swine of the ISA 206/DDA group (~~Fig. 3~~) provided high and relatively uniform levels of antibody responses. Immunocastration levels of testosterone in this group were achieved by week 9 and stably maintained through week 12. Both animals were responsive to the boost at week 13  
25 and maintained castration levels of testosterone. The testes of both animals were undetectable by week 23.

30 From the results obtained the ISA 206/DDA formulation is, thus, most preferred for prevention of boar taint. High and uniform effects on the two animals are achieved with the ISA 206/DDA formulation. Moreover, the formulation is more acceptable in swine in comparison to the IFA formulation which caused lesions, apparently because the IFA formulation is not readily metabolized.

CL U/C

35

CL U/L

#### EXAMPLE 4

SOMATOSTATIN IMMUNOGENS

C/L

FOR GROWTH PROMOTION IN FARM ANIMALS

Immunogens of the invention may be used singly or in combination to elicit antibodies to somatostatin.

Somatostatin is a major inhibitor of total somatic growth. It is a cyclic peptide hormone of fourteen amino acids (SEQ ID NO:80, Table 5) and its structure is conserved across species.

Somatostatin inhibits the release of many gastro-intestinal hormones as well as inhibits the release of growth hormone, insulin, and thyroid hormones, thereby affecting both the ability of the animal to absorb nutrients and its subsequent ability to direct these nutrients into tissue growth. The neutralization of somatostatin by immunization has been shown to stimulate growth in sheep, goats, chickens, and pigs (Spencer, *Dom Anim Endocr*, 1986; 3:55; Spencer et al., *Reprod Nutr Develop*, 1987; 27(2B):581; Laarveld et al., *Can J Anim Sci*, 1986, 66:77), and cattle (Lawrence et al., *J Anim Sci*, 1986, 63(Suppl): 215).

In addition to stimulating growth rate and leading to a 20% reduction in rearing time (Spencer, 1986; Spencer et al., 1987) active immunization against somatostatin also has a beneficial effect the efficiency of food conversion, i.e., in addition to the saving on feed by virtue of more rapid growth, the animals actually utilize their food more efficiently during the growing period, at least partly as a result of changes in gut motility (Fadlalla et al., *J Anim Sci*, 1985, 61:234). The treatment does not have any marked effect on carcass composition (Spencer et al., 1987) but there were indications that, when killed at equal weights, treated animals may be less fatty and leaner. Taken all of the experimental data together, effective active immunization to somatostatin (as evidenced by the presence of anti-somatostatin antibodies) is a powerful, safe, and effective tool to enhance growth (Spencer, 1986).

However, somatostatin is a short peptide and a self-antigen and is non-immunogenic by itself (see Table 5).

Nevertheless, several immunogenic forms of somatostatin have been designed and tested as reported in the literature. For example, somatostatin has been conjugated with protein carriers to enhance immunopotency. However, protein carriers are too expensive for economical use in farm animals. Further, effective immunization with somatostatin is highly dependent on how the carrier is conjugated to somatostatin. In most cases, glutaraldehyde is employed as the carrier for coupling with the lysine residues present on somatostatin and glutaraldehyde. The two lysines on somatostatin available for coupling reside within a 12-mer functional loop. The conjugation of these lysines may result in significant loss of the native somatostatin structure. As a result, cross-reactivity to natural somatostatin with the antibodies is reduced. Moreover, with protein carriers, the majority of immune responses are directed to the carrier rather than to somatostatin (the mass of the carrier molecule(s) is much greater than that of somatostatin). Immunization with a small peptide carrier conjugates has frequently led to carrier-induced immune suppression (Schutz et al., *J Immunol*, 1985, 135:2319). Accordingly, there is a need for a different way to enhance the immunogenicity that is more suitable for farm animal use. The vaccine should be inexpensive and capable of stimulating an early and strong immune response to somatostatin and avoid carrier-induced suppression.

The somatostatin/Th epitope peptide immunogens shown in Table 5 were synthesized and administered to rats. The effect of the immunization was determined by peptide ELISA as described in EXAMPLE 1. Cyclized Somatostatin was used in one of the peptide immunogen (SEQ ID NO:80) tested and in the assay as the solid-phase substrate in ELISA. To completely cyclize somatostatin, the cleaved peptide was dissolved in 15% DMSO in water for 48 hrs to facilitate intra-disulfide bond formation.

From the results shown in Table 5, it is clear that somatostatin alone is devoid of immunogenicity whereas the

peptide immunogens of the present invention elicited high titers of somatostatin-specific antibodies in the immunized hosts. The anti-somatostatin responses generated for SEQ ID NO:81-83, SEQ ID NO:84-86 and SEQ ID NO:87, with Th epitopes (SEQ ID NOS:6,7,8 and 31) show the effectiveness of the Th epitopes. However, a close comparison of the antibodies titers for immunogenicity show that it is preferable to place the Th epitope on the C-terminus. The results for SEQ ID NOS:84-86, with the Th epitope as SEQ ID NOS:6,7,8 show an earlier higher level of antibodies was elicited. The results of Table 5 illustrate the strong antibody response to immunization with artificial Th/somatostatin compositions, thereby establishing the utility of these peptides of this invention for growth promotion in farm animals.

EXAMPLE 5

PEPTIDE COMPOSITION FOR PREVENTION OF HIV INFECTION

Peptide immunogens comprising idealized artificial Th sites of the present invention and a target antigenic site cross-reactive to a host cell receptor/co-receptor complex for HIV may be used to elicit antibodies to that host cell complex in the immunized host. Said complex which is located on the surface of host lymphocytes expressing CD4 comprise CD4 associated with a chemokine receptor domain. This complex is the primary receptor for entry of HIV into T cells. Antibodies directed to this CD4 complex block the interactions between HIV and its receptor, and the interactions between CD4-Class II and CD4-expressing T cells and other activated T cells. Thus, antibodies directed to this complex have broad neutralizing activities against primary isolates of HIV-1, HIV-2, and SIV and intervene in the immunosuppression of CD4+ cell-mediated immune responses (WO 97/46697).

The peptide immunogens relevant to the CD4 complex antigenic site may be formulated singly or in combination for the generation, by active immunization in mammals including

humans, high titers of serum antibodies to the CD4 complex. These antibodies are useful for the prevention and treatment of immunodeficiency virus infection as well as for treatment of undesirable immune responses such as transplant rejection, rheumatoid arthritis, systemic lupus erythematosus, and psoriasis.

An artificial Th epitope/target antigenic site peptide immunogen was designed with a sequence modified from the CDR2-like domain of CD4 as the target antigenic site. The modified site comprises a peptide sequence taken from the CDR2-like domain of human CD4 (amino acids 39-66 according to the numbering system of Maddon et al., *Cell*, 1985; 42:93; and, Littman et al., *Cell*, 1988; 55:541) modified as follows: (1) the insertion of cysteine residue to the N-terminus side of position 39 of the naturally occurring CD4 sequences, (2) the insertion of a cysteine residue at the C-terminus side of position 66 thereof, and (3) the formation of a disulfide bond between the inserted cysteines to produce a cyclic structure.

The optimized and modified (i.e., cyclized) target site for CD4-CDR2 of the following sequence is provided:

pl 1. Cys-Asn-Gln-Gly-Ser-Phe-Leu-Thr-Lys-Gly-Pro-Ser-Lys-Leu-Asn-Asp-Arg-Ala-Asp-Ser-Arg-Arg-Ser-Leu-Trp-Asp-Gln-Gly-Asn-Cys

pl 2. (SEQ ID NO:88)

25 To complete the cyclization, the modified peptide was dissolved in 15% DMSO in water for 48 hrs to facilitate intra-disulfide bond formation between the cysteines. SEQ ID NO:84 was incorporated into the peptide immunogen:

ti (SEQ ID NO:6,7,8)-GG-(SEQ ID NO:88)

30 (SEQ ID NO:89-91)

p Immunogenicity in guinea pigs of SEQ ID NO:85 formulated in ISA 206/DDA, 100 µg/dose, given at weeks 0, 3, 6, was evaluated. Immunogenicity was determined by peptide ELISA as described in EXAMPLE 1. The cyclized target antigenic site peptide used as the solid-phase substrate in the ELISA. The labeled conjugate was specific for guinea pig IgG. Six of

six guinea pigs were successfully seroconverted by the ELISA reactivity obtained. It is significant that SEQ ID NO:85 was found to be highly immunogenic and is functional in a large animal.

- 5                   An immunogenic composition comprising SEQ ID NO:85 was formulated in IFA, 300µg/dose, and administered to a swine by intramuscular injection on weeks 0, 3, and 6. The swine seroconverted and the serum from week 8 was tested for neutralization activity against a primary isolate of HIV-1.
- 10                  Neutralization activity was assayed on HIV-1 VL135, a primary isolate of subtype B, by MT-2 Microplaque Neutralization Assay (Hanson et al., J Clin Microbiol, 1990; 28:2030; WO 97/46697).
- 15                  The swine serum sample provided 50% virus neutralization at a dilution of 1:249, and 90% neutralization at a dilution of 1:97. Therefore, immunization of a large animal host with a peptide immunogen composition of the present invention produced antibodies which bind to the host cell receptor comprising CD4 and neutralize HIV.

CL V/C

EXAMPLE 6

CL V/L

PEPTIDE COMPOSITION FOR TREATMENT OF ALLERGY

- Peptide immunogens comprising the idealized
- 5 artificial Th sites of the invention and a target antigenic site that cross-reacts with an effector site on the third constant domain (CH3) of the epsilon (E) heavy chain of IgE are provided. The immunogens may be used to elicit auto-antibodies to the IgE effector site in the immunized host.
- 10 That IgE-CH3 effector site is modified from a segment of the CH3 domain of the epsilon (E) heavy chain of human IgE (amino acids 413-435 (Dorrington and Bennich, 1978; 41:3). It is modified from that of the naturally occurring IgE sequence as follows: (1) insertion of a cysteine residue to the N-
- 15 terminus side at position 413, (2) substitution for the native cysteine at position 418 of the native IgE sequence by serine, (3) insertion of cysteine at C-terminus side at position 435, and (4) formation of a disulfide bond between the cysteines at the N- and C- termini to produce a cyclic structure. By this
- 20 process the target antigen site for human IgE is optimized.
3. **Cys**-Gly-Glu-Thr-Tyr-Gln-Ser-Arg-Val-Thr-His-Pro-His-
4. Leu-Pro-Arg-Ala-Leu-Met-Arg-Ser-Thr-Thr-Lys-**Cys**

(SEQ ID NO.:92)

- Amino acid substitutions from the natural sequence
- 25 are shown in boldface. The results show that the polyclonal antibodies elicited have specificity for the CH3 effector site of IgE in the immunized host. They prevent the sensitization of mast cells and basophils by IgE, thereby preventing the triggering and activation of mast cells/basophils and leading
- 30 to the down-regulation of IgE synthesis. Moreover, antibodies elicited by peptides shown in Table 6 comprising this target antigenic site are cross-reactive with human IgE, and these antibodies are safe and non-anaphylactogenic. Furthermore, the antibodies do not crosslink to IgE bound to the high



affinity cell receptor to induce degranulation.

The peptide conjugates relevant to the IgE-CH3 antigenic site may be formulated singly or in combination and used to immunize mammals including humans to generate high  
5 titers of serum antibodies, which are useful for the prevention and treatment of allergic symptoms.

The peptide immunogens incorporating the modified IgE-CH3 target site (SEQ ID NO:92) are shown in Table 6 as SEQ ID NOS:87-90. These peptide immunogens were used to immunize  
10 groups of 3 guinea pigs using 100µg/dose, formulated in CFA at week 0, IFA at weeks 3 and 6, and administered intramuscularly. For comparison, a group of two animals were immunized with a peptide/KLH carrier protein conjugate at 200µg/dose, similarly administered. ELISA results of serum  
15 samples collected at week 8 are shown. In the ELISA a human IgE myeloma protein (American Biosystem, Inc. cat. no. A113) was used as the solid-phase immunoabsorbant. The procedure used was identical to the peptide-based ELISAs described previously, except IgE myeloma was used as the solid phase  
20 immunoabsorbant. Thus, the results demonstrate cross-reactivity with human IgE. The ELISA results also demonstrate that all of the constructs were immunogenic with cross-reactivity for human IgE, with the peptide immunogens of the present invention providing superior immunogenicity. The  
25 inclusion of the Inv domain sequence (SEQ ID NO:78) augmented the immunogenicity, as shown by the enhanced immunogenicity of SEQ ID NO:99 over SEQ ID NO:98.

To test the anti-human IgE antibodies in assays for biological activity and safety, guinea pig hyperimmune sera  
30 were produced against SEQ ID NO:98 and 99. The procedure is as described above, except that the animals also received a booster dose of the peptide immunogen in IFA on week 10. Guinea pig IgG antibodies were purified and the ability of the purified antibodies to inhibit the sensitization of human  
35 basophils by allergen-specific IgE determined as follows.

Guinea pig IgG antibodies were purified by Protein A affinity chromatography (ImmunoPure® Immobilized Recomb® Protein A, Pierce) from serum collected at weeks 8 and 12. The serum from the animals immunized with SEQ ID NOS 98, 99 were pooled. The eluted antibodies were prepared at a standard concentration of 8mg/mL in 25mM PIPES buffer, 0.15M NaCl, pH 7.2. A control antibody preparation was prepared from the pooled serum of guinea pigs immunized with an irrelevant peptide immunogen. These antibodies were used in assays that measure the reduction in IgE-mediated sensitization of human basophils. Human basophils were prepared from the venous blood of volunteers using centrifugation through Percoll density gradients (MacGlashan. J Allergy Clin Immunol, 1993; 91:605-615). The banded leukocytes were collected, washed, and resuspended in 0.1mL of PAGCM buffer as describe (MacGlashan, 1993) except that the PAGCM buffer used to suspend the cells was made up with water containing 44% D<sub>2</sub>O. The IgE used for the assay was allergen-specific, either human BPO-specific IgE or chimeric human IgE having grafted variable domains with specificity for HIV glycoprotein gp120. The allergen-specific IgE at 0.25µg/mL was preincubated for 15 minutes at 37°C with an equal volume of the purified antibody at 8mg/mL. The total volume was 0.1mL. The antibody mixture was added to the and incubated for 20 minutes to allow for sensitization of the basophils by uncomplexed IgE. The sensitized were then stimulated by addition of the allergen, either BPO<sub>21</sub>-HSA or a gp120 polypeptide as described (MacGlashan, 1993). After an appropriate incubation period (usually 45 minutes), the basophils were separated from the supernatant and the supernatant assayed for histamine content by an automated fluorimetric technique (Siraganian, Anal Biochem, 1974; 57: 383-394). All reactions were performed in duplicate. The percent histamine release was calculated from the ratio of sample to total histamine minus from both the amount of spontaneous histamine release. The histamine

release by experimental antibody to histamine release by the control antibody of irrelevant specificity was compared and the ratio obtained. (Histamine release assays on human basophils were kindly performed under coded conditions by Dr. Donald W. MacGlashan, The Johns Hopkins University School of Medicine, Johns Hopkins Asthma and Allergy Center, Baltimore).

Specific inhibition of histamine release by the site-specific anti-IgE was 61% and 71% for the antibodies purified from bleeds taken on weeks 8 and 12, respectively.

10           These actively induced polyclonal antibodies were then further tested for safety. They were tested for ability or inability to cross-link receptor-bound IgE and induce spontaneous histamine release in the absence of allergen. This establishes whether or not they are non-anaphylactogenic  
15 anti-IgE antibodies. A preparation of guinea pig anti-SEQ ID NO:98 was tested by direct challenge of IgE-sensitized basophils, in the absence of allergen, to evaluate its ability to crosslink receptor-bound IgE and induce degranulation. Histamine release by anti-SEQ ID NO:98 was equivalent to the  
20 level of spontaneous histamine release by the donor cells. Based on this result, it was concluded that antibody of specificity for the target antigen site of SEQ ID NO:98, i.e., SEQ ID NO:92, is non-anaphylactogenic.

          The 12 week anti-SEQ ID NO:98 preparation was also  
25 evaluated for IgE-specificity, to determine the potential of these antibodies for isotype specific immunosuppression. The cross-reactivity of anti-SEQ ID NO:98 guinea pig antibodies to human IgE and IgG were compared by ELISA. The procedure is described for human IgE. For human IgG ELISA, human IgG was  
30 used as the solid-phase immunosorbent.

          The IgE ELISA plates were coated with the human IgE myeloma at 5µg/mL. For the IgG ELISA, the plates were coated with human purified IgG (Sigma reagent grade human IgG), also at 5µg/mL. The purified guinea pig anti-SEQ ID NO:98 was  
35 tested for reactivity in both ELISAs at concentrations of 0.5

and 0.1µg/mL. Results were compared to antibodies purified from control guinea pig serum and to a "no antibody" control.

The A<sub>490</sub> values obtained for anti-SEQ ID NO:98 antibody on IgE were 1.126 at 0.5µg/mL and 0.344 at 0.1µg/mL. The A<sub>490</sub> values  
5 obtained for anti-SEQ ID NO:98 antibody on IgG were equal to control antibody and background values. This shows that there was no cross reactivity of the guinea pig anti-SEQ ID NO:98 to human IgG.

The peptide immunogen composition of the present  
10 invention did not elicit antibodies that recognize IgG antibodies, and therefore are isotype specific for IgE. Thus, it can be concluded that active immunization with Th/IgE target antigenic site immunogens of the invention elicit safe non-anaphylactogenic anti-IgE antibodies. The antibodies were  
15 effective in inhibiting IgE-mediated sensitization, and displayed an immunosuppressive potential specific to antibodies of isotype IgE.

EXAMPLE 7PEPTIDE COMPOSITION FOR PREVENTION  
OF FOOT-AND-MOUTH DISEASE

5           Peptide immunogens comprising idealized artificial  
Th sites of the invention and a target antigenic site cross-  
reactive to the "G-H Loop" on the VP1 capsid protein of Foot-  
and Mouth Disease Virus (FMDV), may be used to elicit  
neutralizing antibodies to FMDV.

10           Foot-and-mouth disease (FMD) is the most  
economically important disease of domestic livestock. Cloven-  
hoofed species including cattle, pigs, sheep and goats are  
susceptible. Seven distinct serotypes have been described: A,  
O, C, Asia, and the South African types SAT-1, 2, and 3, each  
15 of which can be subdivided into multiple subtypes. Viruses of  
serotypes A, O, and Asia-1 are most common. Serotype A  
viruses are the most variable, having more than 30 subtypes.  
There is no cross-protection between serotypes so that animals  
recovered from infection with or vaccinated against a virus of  
20 one serotype are still susceptible to infection with viruses  
from the remaining six serotypes. Moreover, the degree of  
antigenic variation within a serotype is such that a vaccine  
made against one subtype may not be protective for another  
subtype within that same serotype (Brown, Vaccine, 1992;  
25 10:1022-1026).

          Serotype-specific peptides corresponding to the 141-  
160 region (the G-H Loop) of the VP1 capsid proteins of  
isolates belonging to all seven FMDV serotypes have been shown  
to elicit protective levels of type-specific neutralizing  
30 antibodies in guinea pigs (Francis et al., *Immunology*, 1990;  
69:171-176). Clearly this region contains a dominant  
immunogenic site which also carries the serotype specificity  
of the virus. The initial observations of immunogenicity for  
these 141-160 VP1 peptides was accomplished using synthetic

peptides conjugated to carrier protein KLH (keyhole limpet hemocyanin), a procedure which negates the advantage of manufacturing a well-defined synthetic immunogen. However, the development of VP1 synthetic immunogens was advanced by DiMarchi and Brook (U.S. Patent No. 4,732,971) who showed that two VP1 sequences from a subtype O isolate, joined in a 200-213 Pro-Pro-Ser-141-158-Pro-Cys-Gly (SEQ ID NO:100) chimeric construct, elicited antibody levels which protected cattle against challenge. Nevertheless, the efficacy of this effect was limited by the low immunogenicity of the peptide immunogen and by its narrow serotype specificity. Practical application demands that a vaccine formulation provide protection from both homotypic and heterotypic exposure, with small amounts of peptide immunogen.

The G-H Loop immunodominant site optimized for immunogenicity and capacity to induce broadly neutralizing antibodies is incorporated as a target antigenic site into the peptide immunogens of the present invention. The site is homologous to amino acid positions 134-169 on the FMDV VP1 protein of strain A12 (Robertson et al, *J Virol*, 1985; 54:651-660) and extend beyond either end of the G-H Loop. The target site was further modified by: (1) substitution of Asp at position 134 and Gln at position 157 with cysteines, (2) formation of a disulfide bond between the substituent cysteines to produce a cyclic structure, and (3) construction of an SSAL thereof using the corresponding VP1 sequences from a selection of subtypes. The optimized target antigen sites for the FMDV VP1 are exemplified by the peptides listed in Table 7. The two peptide immunogens, SEQ ID NO:101 and SEQ ID NO:102, are SSAL target antigenic sites compiled from strains of FMDV serotypes O and Asia, respectively. The target antigenic sites of both serotype O and Asia were coupled to the Th epitopes of the present invention, SEQ ID NO: 31. The Inv domain sequence (SEQ ID NO:78) was also incorporated into SEQ ID NO:102.

These two SSAL peptide immunogens were synthesized and used to hyperimmunize groups of three Duncan Hartley guinea pigs (female, 9 weeks old, 450 gm, virus free). Each animal was immunized with 100µg per dose of the indicated synthetic construct emulsified in CFA at week 0 or IFA at weeks 3 and 6. The animals were bled on weeks 0, 5 and 10 for testing.

Serum samples were obtained from five and 10 week bleeds and pooled from each group. The pooled sera were evaluated for reactivity to the VP1 neutralizing epitope by peptide based ELISA using a peptide having the sequences for the neutralizing epitope (VP1 134-169) as the solid phase immunoabsorbant. Their ability to neutralize FMDV strains A1 A12<sub>FP</sub>, A<sub>FL</sub>, A23, O-1<sub>JH</sub>, O-1<sub>P2</sub>, and Asia-1 were also determined. The virus neutralizing activity of a 1:100 dilution of a serum sample was determined by observing neutralization on a series of increasing input viral loads, using aliquots (10,000 MPD<sub>50</sub>) of the virus strains named above. The results are shown in Table 7. The testing method performed (Morgan and Moore, Am J Vet Res, 1990; 51:40-45), demonstrated that immunization with the peptide antigens of the present invention provided sera which reduced by 2.5 Log<sub>10</sub> FMDV microplaques at 1:100 dilution. The results also are highly predictive of protective immunity against FMDV infection.

As shown by Table 7, high anti-peptide titers against the target antigenic sites (>5 Log<sub>10</sub>) were elicited by week 5. Broad and effective neutralization of all seven tested strains belonging to three different FMDV serotypes (i.e., A, O, Asia) were observed, despite the wide variations between these strains and serotypes.

This further demonstrates the efficacy of the artificial Th epitopes of the present invention to stimulate effective antibody responses against an epitope from a foreign pathogen.

EXAMPLE 8PEPTIDE COMPOSITION OF A SPOROZOITE MALARIA VACCINE

Peptide immunogens comprising the idealized artificial Th sites and a circumsporozoite (CS) target antigen from *Plasmodium falciparum*, a human malaria parasite, are provided. The CS protein is the major surface antigen of the sporozoite stage of the parasite. Immunologic studies and sequence data on a large number of CS genes of human, simian, and rodent plasmodia have been documented showing that all CS proteins contain a central region, consisting of a series of tandem repeats, encompassing multiple copies of an immunodominant B cell epitope. In *P. falciparum* the repeating epitope is represented as

(Asn-Ala-Asn-Pro)<sub>n</sub>

Antibodies directed against the repeats of the CS protein of the human malaria parasites, *P. falciparum* and *P. vivax*, inhibit the invasion of hepatocytes by sporozoites and abolish their infectivity. Therefore, repeats of the CS epitope have been the target antigen of subunit vaccines used in various human malaria vaccine trials (Nussenzweig et al., *Adv. Immunol.*, 1989, 45:283; Hoffman et al., *Science*, 1991, 252:520). However, one of the shortcomings of the various synthetic malaria vaccines currently in clinical trials is their low immunogenicity. Thus, a potential malaria vaccine remains to be developed. (Calvo-Calle et al., *J Immunol*, 1994, 150:1403)

To overcome the immunogenicity problem associated with the repeats of the CS protein of *P. falciparum*, the artificial Th epitopes shown in Table 1 are incorporated into the CS peptide immunogens. For example, peptide construct (SEQ ID NOS:15,18)-□Nlys-(Asn-Ala-Asn-Pro)<sub>4</sub> (SEQ ID NOS:104,105)

is synthesized and used as the key immunogen in a malaria vaccine to elicit potent protective antibodies in



small animals, primates (e.g., baboons) and humans against *P. falciparum* sporozoites.

#### EXAMPLE 9

5            PEPTIDE COMPOSITION FOR PREVENTION AND TREATMENT OF  
             ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE

             Cholesteryl ester transport protein (CETP) mediates  
the transfer of cholesteryl esters from HDL to TG-rich  
lipoproteins such as VLDL and LDL, and also the reciprocal  
10        exchange of TG from VLDL and LDL (Tall, *J Internal Med*, 1995,  
237:5-12; Tall, *J Lipid Res*, 1993, 34:1255; Hesler et al., *J*  
*Biol Chem*, 1987, 262:2275; Quig et al., *Ann Rev Nutr*, 1990,  
10:169). CETP may play a role in modulating the levels of  
cholesteryl esters and triglyceride associated with various  
15        classes of lipoproteins. A high CETP cholesteryl ester  
transfer activity has been correlated with increased levels of  
LDL-associated cholesterol and VLDL-associated cholesterol,  
which in turn are correlated with increased risk of  
cardiovascular disease (see, e.g., Tato et al., *Arterioscler*  
20        *Thromb Vascular Biol*, 1995, 15:112).

             CETP isolated from human plasma is a hydrophobic  
glycoprotein having 476 amino acids. A cDNA encoding human  
CETP has been cloned and sequenced (Drayna et al., *Nature*,  
1987, 327:632). A monoclonal antibody TP2 (formerly  
25        designated 5C7) has been produced which completely inhibits  
the cholesteryl ester and triglyceride transfer activity of  
CETP and, to a lesser extent, the phospholipid transfer  
activity (Hesler et al., *J Biol Chem*, 1988, 263:5020). The  
epitope of TP2 was localized to the carboxyl terminal 26 amino  
30        acids, i.e., the amino acids from Arg451 to Ser476 of human  
CETP (see, Hesler et al., 1988):

             Arg Asp Gly Phe Leu Leu Leu Gln Met Asp  
             Phe Gly Phe Pro Glu His Leu Leu Val Asp  
             Phe Leu Gln Ser Leu Ser

(SEQ ID NO:106)

TP2 was reported to inhibit both human and rabbit CETP activity in vitro and rabbit CETP in vivo (Yen et al., *J Clin Invest*, 1989, 83:2018). Further analysis of the region of CETP bound by TP2 revealed that amino acids between Phe463 and Leu475

Phe Gly Phe Pro Glu His Leu Leu Val Asp Phe Leu Gln Ser Leu  
Ser

(SEQ ID NO:107)

are necessary for TP2 binding and for neutralizing CETP neutral lipid binding and transfer activity (see, Wang et al., *J Biol Chem*, 1992, 270:612).

A number of in vivo studies utilizing animal models or humans have indicated that CETP activity can affect the level of circulating cholesterol-containing HDL. Increased CETP cholesteryl ester transfer activity can produce a decrease in HDL-C levels relative to LDLC and/or VLDLC levels and low HDL which in turn is correlated with an increased susceptibility to arteriosclerosis. Therefore, the discovery of compounds and methods to control CETP activity will be advantageous in preventing or treating cardiovascular disease.

Rittershaus et al., WO 96/34888, proposed the use of a peptide composition comprising a "universal" or "broad range" immunogenic helper T cell epitope linked, preferably covalently, to a B cell epitope portion such as the one found in the carboxyl terminal portion of human CETP involved in a neutral lipid binding or transfer activity of CETP. In order to enhance the immunogenicity of the functional site on human CETP, i.e., the carboxyl terminal amino acids of human CETP (SEQ ID NOS:96 and 97) and peptide analogues thereof linked to the antigenic peptides comprising artificial Th epitopes from Table 1 and CETP target antigen peptides were synthesized. These peptide antigens, shown in Table 8, are used to elicit antibodies to CETP in small animals, primates and humans. Anti-CETP antibodies control CETP activity. Thereby, the CETP antigenic peptides are expected to cause reduced accumulation

in plasma of LDL-associated cholesterol and provide protection from and treatment of arteriosclerosis and coronary heart disease.

#### EXAMPLE 10

##### 5            PEPTIDE COMPOSITION AS HIV VACCINE COMPONENT FOR THE ELICITATION OF NEUTRALIZING ANTIBODIES AGAINST HIV

Progress in the development of an effective vaccine for HIV-1 has been gauged in large part by measuring the  
10 ability to induce measurable virus-specific CD8<sup>+</sup> cytotoxic T lymphocytes (CTLs) and neutralizing antibodies, the leading indicators of a protective immune response. A strong correlation was observed between protection against infection and levels of neutralizing Abs in nonhuman primates infected  
15 with HIV-1 or simian HIV (SHIV). However, little progress has been made in generating neutralizing antibodies over the past decades. Part of the problem is the weak neutralizing antibody response generated by candidate HIV-1 vaccines. A recent article entitled "Toward an HIV Type 1 vaccine that  
20 generates potent, broadly cross-reactive neutralizing antibodies" by Montefiori et al (*AIDS Res and Hum Retrovir*, 1999, 15:689-698) provides a state-of-the-art review of the difficulties encountered in HIV vaccine development.

In an effort to enhance the neutralizing antibody  
25 response against HIV, we embarked on synthetic antigen designs aimed at eliciting potent neutralizing antibodies. The synthetic antigens employ specially designed artificial Th epitopes as the immune stimulatory element of the construct covalently linked to HIV neutralizing B cell epitopes (e.g.  
30 Korber et al, *HIV Mol Immunol Database 1997, Part III Antibody Binding Sites*) or neutralizing mimetopes (e.g. Scala et al, *J Immunol* 1999, 162: 6155-6161) previously recognized by either monoclonal or polyclonal antibodies.

Amongst the HIV neutralizing B cell epitopes, an  
35 artificial V3 consensus sequence was designed (SEQ ID NO: 125)

comprising an optimal frame of the V3 principal neutralizing determinant of HIV gp120 (Wang, C.Y., US 5,763,160). These include the most frequent amino acid for each of the amino acid positions within that frame based on analyses of amino acid sequences from over 1,000 HIV isolates from subtypes A to G, along with sequences derived from linear or conformational epitopes of HIV gp120/ gp41 regions shown here in Tables 9 and 10 in SEQ ID NOS:125, 126-129, 148-153. The neutralizing mimetopes of Scala et al (SEQ ID NOS:130-135) are also synthesized as peptides of the invention, SEQ ID NOS:136-147, as shown in Table 9.

The immunogenic peptide constructs of the invention shown in Table 10 are wholly synthetic and were synthesized by the solid-phase method outlined in Example 1. These immunogenic peptide constructs further illustrate the utility of the artificial Th of the present invention in HIV vaccine development.

Each peptide in Table 10 can be represented by the formula  $(A)_n-(Th)_m-(B)_o-(HIV\ B\ neutralizing\ epitope)-X$  or  $(HIV\ neutralizing\ epitope)-(B)_o-(Th)_m-(A)_n-X$ . The HIV neutralizing epitopes include SEQ ID NOS: 125 and 130-135. The immunogenic peptides comprise one or more Th sites derived from artificial Th (as shown in Table 1). Each peptide of this example have Gly-Gly or  $(\epsilon-N)Lys$  spacers between immunogenic elements, but peptides of the invention may have other spacers or no spacers.

Peptides of these examples may comprise an optional Inv immunostimulatory site (SEQ ID NO: 27). It is understood however that the invention is not limited to the use of Inv as an additional immunostimulatory element.

Representative peptide constructs of the invention as listed in Table 10 (SEQ ID NOS: 148-153) were synthesized, cleaved, cyclized and purified as described in Example 1. Each peptide construct was formulated for immunization into small animals such as guinea pigs, or into larger animals such

as pigs or baboons for evaluation of its immunogenicity. Each of the peptides was suspended in a volume of 0.5 mL containing representative emulsifiers or adjuvants such as ISA51, ISA720, DDA or monophosphoryl lipid A (MPL). The dose was 100 µg of peptide for guinea pigs or 300 µg of peptide for swine or baboons and the animals were immunized intramuscularly.

Animals received injections on weeks 0, 3 and 6 as specified in Table 10. Test bleeds at 5, 8, 10 and 11 weeks post initial immunization were evaluated for reactivities with target epitopes by B cell epitope peptide ELISA as described in Example 1, and further tested for their ability to neutralize HIV-1 as described in details in Example 5.

All peptides tested elicited strong site-directed cross reactivities to the corresponding target peptide, as shown by Log<sub>10</sub> titers on the anti-B epitope peptide ELISAs of greater than 4. Neutralization of HIV-1 was also observed for immune sera obtained from guinea pigs, and baboons. This functional reactivity by the baboon sera is noteworthy inasmuch as the neutralization of human HIV by the baboon sera is nearly a human system. The results are strong indicators of the efficacy of a peptide construct of the invention as an agent for the prevention and/or immunotherapy of HIV infection by active immunization.

Table 1

## Model, Prototype, and Artificial Idealized Th Epitopes

## a. MVF Th and Th epitopes derived therefrom

| Th Identifier |             | Amino Acid Sequence     |
|---------------|-------------|-------------------------|
| MVF Th        | SEQ ID NO:1 | LSEIKGVIVHRLEGV         |
| SSAL1 Th1     | SEQ ID NO:2 | DLSDLKGLLLHKLDGL        |
|               | SEQ ID NO:3 | EI EIR <u>III</u> RIE I |
|               | SEQ ID NO:4 | V V <u>VV</u> V V       |
|               | SEQ ID NO:5 | F F <u>FF</u> F F       |
| SEQ ID NO:6   |             | ISEIKGVIVHKIEGI         |
| SEQ ID NO:7   |             | MT RT TRM TM            |
| SEQ ID NO:8   |             | L L V                   |
| SEQ ID NO:6   |             | ISEIKGVIVHKIEGI         |
| SEQ ID NO:9   |             | T RT TR T               |
| SEQ ID NO:10  |             | MSEIKGVIVHKLEGM         |
| SEQ ID NO:11  |             | LT MRT TRM TV           |
| SEQ ID NO:6   |             | ISEIKGVIVHKIEGI         |
| SEQ ID NO:12  |             | ITEIRTVIVTRIENTI        |
| SEQ ID NO:13  |             | MSEMKGIVVHKMEGM         |
| SEQ ID NO:14  |             | LTEIRTVIVTRLETV         |
| SEQ ID NO:15  |             | ISISEIKGVIVHKIEGILF     |
| SEQ ID NO:16  |             | MT RT TRM TM            |
| SEQ ID NO:17  |             | L L V                   |
| SEQ ID NO:15  |             | ISISEIKGVIVHKIEGILF     |
| SEQ ID NO:18  |             | T RT TR T               |
| SEQ ID NO:19  |             | ISLSEIKGVIVHKLEGMFL     |
| SEQ ID NO:105 |             | MT MRT TRM TV           |
| SEQ ID NO:123 |             | ISLTEIRTVIVTRLETVLF     |
| SEQ ID NO:124 |             | I I I                   |
| SEQ ID NO:15  |             | ISISEIKGVIVHKIEGILF     |
| SEQ ID NO:20  |             | ISITEIRTVIVTRIENTILF    |
| SEQ ID NO:21  |             | ISMSEMKGIVVHKMEGMFL     |
| SEQ ID NO:22  |             | ISLTEIRTVIVTRLETVLF     |

## b. HBsAg Th, Prototype and Derivatives

| Th Identifier |              | Amino Acid Sequence         |
|---------------|--------------|-----------------------------|
| HbsAg.Th      | SEQ ID NO:23 | FFLLTRILTIPOSLD             |
|               | SEQ ID NO:24 | KKKFFLLTRILTIPOSLD          |
|               | SEQ ID NO:25 | FFLLTRILTIPOSL              |
| SSAL2 Th2     | SEQ ID NO:26 | KKKLFLLTKLLTLPOSLD          |
|               | SEQ ID NO:27 | RRRIKII <u>RII</u> I L IR   |
|               | SEQ ID NO:28 | VRVV <u>VV</u> V I V        |
|               | SEQ ID NO:29 | F <u>FF</u> <u>FF</u> F V F |
|               | SEQ ID NO:30 | F                           |
| SEQ ID NO:31  |              | KKKIITITRIITIITID           |
| SEQ ID NO:32  |              | KKKIITITRIITIITTI           |
| SEQ ID NO:33  |              | KKKMMTMTMITMITID            |
| SEQ ID NO:34  |              | FITMDTKFLLASTHIL            |
| SEQ ID NO:35  |              | KKKFITMDTKFLLASTHIL         |

Table 2  
Immunogenicity of LHRH Peptides

## a. MVF Th Derivatives

| SEQ ID NO: | Description of Antigenic Peptide                             | Formulations                    |      | no. castrated                  |       |
|------------|--|---------------------------------|------|--------------------------------|-------|
|            |  | no. castrated                   |      | no. castrated                  |       |
| 36         | (SEQ ID NO:1)-GG-(LHRH) <sup>a</sup>                         | 400 µg/dose<br>IFA (0,3,6wpi)   | 8/10 | 400 µg/dose<br>Alum (0,3,6wpi) | 5/5   |
| 37         | (SEQ ID NO:2)-GG-(LHRH) <sup>a</sup>                         | 400 µg/dose<br>IFA (0,3,6wpi)   | 9/10 | 400 µg/dose<br>Alum (0,3,6wpi) | 2/5   |
| 38         | (SEQ ID NO:3)-GG-(LHRH) <sup>a</sup>                         |                                 |      |                                |       |
| 39         | (SEQ ID NO:4)-GG-(LHRH) <sup>a</sup>                         |                                 |      |                                |       |
| 40         | (SEQ ID NO:5)-GG-(LHRH) <sup>a</sup>                         |                                 |      |                                |       |
| 41         | (SEQ ID NO:6)-GG-(LHRH) <sup>a</sup>                         | 400 µg/dose )<br>IFA (0,3,6wpi) | 6/6  | 25 µg/dose<br>Alum (0,3,6wpi)  | 3/8   |
| 42         | (SEQ ID NO:7)-GG-(LHRH) <sup>a</sup>                         |                                 |      |                                |       |
| 43         | (SEQ ID NO:8)-GG-(LHRH) <sup>a</sup>                         |                                 |      |                                |       |
| 41         | (SEQ ID NO:6)-GG-(LHRH) <sup>a</sup>                         | N.D.                            |      | 25 µg/dose<br>Alum (0,3,6wpi)  | 1/6   |
| 44         | (SEQ ID NO:9)-GG-(LHRH) <sup>a</sup>                         |                                 |      |                                |       |
| 45         | (Inv) <sup>a</sup> -GG-(SEQ ID NO:6)-GG-(LHRH) <sup>a</sup>  | N.D.                            |      | 25 µg/dose<br>Alum (0,3 wpi)   | 5/5   |
| 46         | (Inv) <sup>b</sup> -GG-(SEQ ID NO:9)-GG-(LHRH) <sup>a</sup>  |                                 |      |                                |       |
| 47         | (SEQ ID NO:10)-GG-(LHRH) <sup>a</sup>                        | 100 µg/dose<br>IFA (0,3,6wpi)   | 4/6  | 25 µg/dose<br>Alum (0,3 wpi)   | 1/8   |
| 48         | (SEQ ID NO:11)-GG-(LHRH) <sup>a</sup>                        |                                 |      |                                |       |
| 45         | (Inv) <sup>a</sup> -GG-(SEQ ID NO:6)-GG-(LHRH) <sup>a</sup>  | N.D.                            |      | 25 µg/dose<br>Alum (0,3 wpi)   | 2/6   |
| 49         | (SEQ ID NO:12)-GG-(LHRH) <sup>a</sup>                        | N.D.                            |      | 25 µg/dose<br>Alum (0,3 wpi)   | 5/6   |
| 50         | (SEQ ID NO:13)-GG-(LHRH) <sup>a</sup>                        | N.D.                            |      | 25 µg/dose<br>Alum (0,3 wpi)   | 0/6   |
| 51         | (SEQ ID NO:14)-GG-(LHRH) <sup>a</sup>                        | N.D.                            |      | 25 µg/dose<br>Alum (0,3 wpi)   | 5/6   |
| 52         | (Inv) <sup>b</sup> -GG-(SEQ ID NO:14)-GG-(LHRH) <sup>a</sup> | N.D.                            |      | 25 µg/dose<br>Alum (0,3 wpi)   | 3/6   |
| 53         | (SEQ ID NO:15)-GG-(LHRH) <sup>a</sup>                        | N.D.                            |      | 25 µg/dose<br>Alum (0,3 wpi)   | 4/8   |
| 54         | (SEQ ID NO:16)-GG-(LHRH) <sup>a</sup>                        |                                 |      |                                |       |
| 55         | (SEQ ID NO:17)-GG-(LHRH) <sup>a</sup>                        |                                 |      |                                |       |
| 53         | (SEQ ID NO:15)-GG-(LHRH) <sup>a</sup>                        | N.D.                            |      | 25 µg/dose<br>Alum (0,3 wpi)   | 6/6   |
| 56         | (SEQ ID NO:18)-GG-(LHRH) <sup>a</sup>                        |                                 |      |                                |       |
| 57         | (Inv) <sup>b</sup> -GG-(SEQ ID NO:15)-GG-(LHRH) <sup>a</sup> | N.D.                            |      | 25 µg/dose<br>Alum (0,3 wpi)   | 6/6   |
| 58         | (Inv) <sup>b</sup> -GG-(SEQ ID NO:18)-GG-(LHRH) <sup>a</sup> |                                 |      |                                |       |
| 59         | (SEQ ID NO:19)-GG-(LHRH) <sup>a</sup>                        | 100 µg/dose                     | 6/6  | 25 µg/dose                     | 14/14 |

Table 2 (Cont'd)

|     |  |                |  |                              |     |
|-----|--|----------------|--|------------------------------|-----|
| 106 | (SEQ ID NO:105)-GG-(LHRH) <sup>a</sup>                       | IFA (0,3,6wpi) |  | Alum (0,3 wpi)               |     |
| 53  | (SEQ ID NO:15)-GG-(LHRH) <sup>a</sup>                        | N.D.           |  | 25 µg/dose<br>Alum (0,3 wpi) | 1/6 |
| 60  | (Inv) <sup>b</sup> -(SEQ ID NO:15)-GG-(LHRH) <sup>a</sup>    | N.D.           |  | 25 µg/dose<br>Alum (0,3 wpi) | 4/6 |
| 61  | (SEQ ID NO:20)-GG-(LHRH) <sup>a</sup>                        | N.D.           |  | 25 µg/dose<br>Alum (0,3 wpi) | 4/6 |
| 62  | (Inv) <sup>b</sup> -GG-(SEQ ID NO:20)-GG-(LHRH) <sup>a</sup> | N.D.           |  | 25 µg/dose<br>Alum (0,3 wpi) | 2/6 |
| 63  | (Inv) <sup>c</sup> -(SEQ ID NO:21)-GG-(LHRH) <sup>a</sup>    | N.D.           |  | 25 µg/dose<br>Alum (0,3 wpi) | 1/6 |
| 64  | (SEQ ID NO:22)-GG-(LHRH) <sup>a</sup>                        | N.D.           |  | 25 µg/dose<br>Alum (0,3 wpi) | 4/6 |

## b. HBsAg Th Derivatives

| SEQ ID NO: | Description of Antigenic Peptide                             | Formulations                  |       |                                 |     |
|------------|--|-------------------------------|-------|---------------------------------|-----|
|            |  | no. castrated                 |       | no. castrated                   |     |
| 65         | (SEQ ID NO:23)-GG-(LHRH) <sup>a</sup>                        | 400 µg/dose<br>IFA (0,3,6wpi) | 10/10 | 400 µg/dose<br>Alum (0,3,6 wpi) | 0/5 |
| 66         | (SEQ ID NO:26)-GG-(LHRH) <sup>a</sup>                        | 400 µg/dose<br>IFA (0,3,6wpi) | 9/10  | 400 µg/dose<br>Alum (0,3,6 wpi) | 2/5 |
| 67         | (SEQ ID NO:27)-GG-(LHRH) <sup>a</sup>                        |                               |       |                                 |     |
| 68         | (SEQ ID NO:28)-GG-(LHRH) <sup>a</sup>                        |                               |       |                                 |     |
| 69         | (SEQ ID NO:29)-GG-(LHRH) <sup>a</sup>                        |                               |       |                                 |     |
| 70         | (SEQ ID NO:30)-GG-(LHRH) <sup>a</sup>                        |                               |       |                                 |     |
| 71         | (SEQ ID NO:31)-GG-(LHRH) <sup>a</sup>                        | N.D.                          |       | 25 µg/dose Alum (0,3 wpi)       | 8/8 |
| 72         | (SEQ ID NO:32)-GG-(LHRH) <sup>a</sup>                        | N.D.                          |       | 25 µg/dose Alum (0,3 wpi)       | 4/6 |
| 73         | (SEQ ID NO:33)-GG-(LHRH) <sup>a</sup>                        | 100 µg/dose<br>IFA (0,3,6wpi) | 4/6   | 25 µg/dose Alum (0,3 wpi)       | 0/6 |
| 74         | (SEQ ID NO:34)-GG-(LHRH) <sup>a</sup>                        | 100 µg/dose<br>IFA (0,3,6wpi) | 6/6   | 25 µg/dose<br>Alum (0,3 wpi)    | 5/8 |
| 75         | (Inv) <sup>b</sup> -GG-(SEQ ID NO:34)-GG-(LHRH) <sup>a</sup> | N.D.                          |       | 25 µg/dose<br>Alum (0,3 wpi)    | 4/6 |
| 76         | (SEQ ID NO:35)-GG-(LHRH) <sup>a</sup>                        | N.D.                          |       | 25 µg/dose<br>Alum (0,3 wpi)    | 0/8 |
|            | KLH <sup>d</sup> -(LHRH) <sup>a</sup>                        | N.D.                          |       | 50 µg/dose Alum (0,3 wpi)       | 2/8 |

- <sup>a</sup> LHRH = EHWSYGLRPG (SEQ ID NO:77)  
<sup>b</sup> INV = Invasin domain (SEQ ID NO:78)  
<sup>c</sup> KLH = Keyhole limpet hemocyanin  
<sup>d</sup> Hinge spacer = PPXPXP (SEQ ID NO:79)



Table 3

Evaluation of Antibody Specificity  
for the Target Antigenic Site

| SEQ ID NO: | LHRH Reactivity <sup>a</sup> | Th Reactivity <sup>b</sup> |
|------------|------------------------------|----------------------------|
| 53 and 56  | 6/6                          | 0/6 <sup>c</sup>           |
| 71         | 8/8                          | 0/8 <sup>d</sup>           |
| 74         | 4/8                          | 0/8 <sup>e</sup>           |

- <sup>a</sup> Number of animals with anti-LHRH titers  
> 1:1000/total animals immunized. The ELISA peptide was SEQ ID NO:77.
- <sup>b</sup> Number of animals with anti-Th reactivity  
> 0.100 A<sub>490</sub> /total animals immunized. Sera were diluted 1:100 and all A<sub>490</sub> values were at background values for the respective Th peptides.
- <sup>c</sup> ELISA peptide was a mixture of two peptides: SEQ ID NOS:15 and 18.
- <sup>d</sup> ELISA peptide was SEQ ID NO:31.
- <sup>e</sup> ELISA peptide was SEQ ID NO:34.

Table 4

Evaluation of Artificial Th/LHRH Peptide Compositions  
Including Mixture

70590

| Immunogen <sup>a</sup>                     | 0 wpi            | 5 wpi | 8 wpi | 10 wpi | 14 wpi | 18 wpi | 22 wpi |
|--|------------------|-------|-------|--------|--------|--------|--------|
| SEQ ID NO:64 + Alum                        | 0/8 <sup>b</sup> | 3/8   | 8/8   | 8/8    | 7/8    | 5/8    | 3/8    |
| SEQ ID NOS:57 and 58 + Alum                | 0/6              | 6/6   | 6/6   | 6/6    | 6/6    | 6/6    | 6/6    |
| SEQ ID NO:64 + SEQ ID NOS:57 and 58 + Alum | 0/6              | 6/6   | 6/6   | 6/6    | 6/6    | 6/6    | 6/6    |

<sup>a</sup> Individual LHRH peptide compositions or the mixed LHRH peptide composition were formulated on alum. Immunization schedule: 25µg/dose at 0 and 3 wpi.

<sup>b</sup> Number of animals immunocastrated/total number of animals in group. Animals were scored as immunocastrated when serum testosterone values were <0.1 nmol/L to undetectable.

Table 5 Immunogenicity of Somatostatin Antigenic Peptides

| SEQ ID NO: | Description of Antigenic Peptide     | Adjuvant              | Immunogenicity   |                |  |
|------------|--------------------------------------|-----------------------|------------------|----------------|--|
|            |                                      |                       | WPI <sup>b</sup> | Responding n=4 | Log <sub>10</sub> ELISA Titer <sup>c</sup> |
| 80         | Somatostatin <sup>a</sup>            | 0.4% Alum (0,2,4 WPI) | 6<br>8           | 0<br>0         | -<br>-                                     |
| 81,82,83   | (SEQ ID NOS:6,7,8)-GG-(Somatostatin) | 0.4% Alum (0,3,6 WPI) | 5<br>8           | 1/4<br>4/4     | 2.38<br>3.33                               |
| 84,85,86   | (Somatostatin)-GG-(SEQ ID NOS:6,7,8) | 0.4% Alum (0,3,6 WPI) | 5<br>8           | 3/4<br>4/4     | 3.24<br>3.12                               |
| 87         | (SEQ ID NO:31)-GG-Somatostatin       | 0.4% Alum (0,3,6 WPI) | 8                | 4/4            | 3.12                                       |

<sup>a</sup> Sequence of somatostatin: AGCKNFFWKFTSC (SEQ ID NO:80)<sup>b</sup> WPI = Weeks post-immunization<sup>c</sup> Test results for pooled sera from ELISA-reactive animals.

Table 6  
Immunogenicity of IgE-CH3 Antigenic Peptides

| SEQ ID NO: | Description of Antigenic Peptide                                   | Immunogenicity |                                      |
|------------|--|----------------|--------------------------------------|
|            |  | No. responding | Log <sub>10</sub> ELISA <sup>b</sup> |
| 93, 94     | (SEQ ID NOS:15, 18)-GG-(SEQ ID NO:92) <sup>a</sup>                 | 3/3            | 3.30                                 |
| 95, 96, 97 | (SEQ ID NOS:6, 7, 8)-GG-(SEQ ID NO:92) <sup>a</sup>                | 3/3            | 3.32                                 |
| 98         | (SEQ ID NO:31)-GG-(SEQ ID NO:92) <sup>a</sup>                      | 3/3            | 2.35                                 |
| 99         | Inv <sup>c</sup> -GG-(SEQ ID NO:31)-GG-(SEQ ID NO:92) <sup>a</sup> | 3/3            | 3.28                                 |
|            | KLH <sup>d</sup> -(SEQ ID NO:92) <sup>a</sup>                      | 2/2            | 0.49                                 |

<sup>a</sup> Modified IgE-CH3 site (SEQ ID NO:92)

<sup>b</sup> Average for animals of the group

<sup>c</sup> Invasin domain peptide (SEQ ID NO:78)

<sup>d</sup> Keyhole Limpet Hemocyanin

Table 7

Artificial Th and SSAL Target Antigenic Peptides for Improved Immunogenicity  
and Breadth of FMDV Neutralization

| SEQ ID<br>NO: | Target Antigenic<br>Peptide  | WPI | No. of<br>Animals<br>Respondi<br>ng<br>(n=3) | Log <sub>10</sub><br>Anti-<br>FMDV-<br>VP1 <sup>d</sup><br>ELISA<br>Titer | Log <sub>10</sub> of FMDV (MPD <sub>50</sub> )<br>Neutralized by Serum <sup>d,e</sup> |             |          |           |          |            |
|---------------|--|-----|--|---|---|-------------|----------|-----------|----------|------------|
|               |  |     |  |   | A <sub>12</sub><br>FP   | O-1<br>(JH) | A-<br>FL | O-1<br>P2 | A-<br>23 | Asi<br>a 1 |
| 101           | (SEQ ID NO:31)-GG<br>-O <sub>complete</sub> SSAL[134-<br>158 (T→C) <sup>a</sup> -169],<br>cyclized             | 5   | 3  | 5.158   | 3.0   | 4.5         | 2.0      |           |          | 5.0        |
|               |  | 10  | 3  |   |   |             |          | 2.5       | 4.5      | 6.0        |
| 102           | Inv-GG-(SEQ ID<br>NO:31)-GG-Asia<br>SSAL[134 (T→C) <sup>b</sup> -<br>158 (R→C) <sup>c</sup> -169],<br>cyclized | 5   | 3  | 5.256   | 3.0   | 4.5         | 2.0      |           |          | 4.5        |
|               |  | 10  | 3  |   |   |             |          | 1.0       | 3.0      | 2.5        |

<sup>a</sup> T<sub>158</sub> of the native sequence was replaced by C.

<sup>b</sup> T<sub>134</sub> of native sequence was replaced by C.

<sup>c</sup> R<sub>158</sub> of the native sequence was replaced by C.

<sup>d</sup> Reactivities of pooled sera from ELISA-reactive animals.

<sup>e</sup> Serum for neutralization assays diluted 1:100.

## CETP ANTIGENIC PEPTIDES

| SEQ ID NO | DESCRIPTION OF ANTIGENIC PEPTIDE                     |
|-----------|--|
| 110,111   | (SEQ ID NOS:15,18)-□NLys-(SEQ ID NO:106)             |
| 112,113   | (SEQ ID NOS:15,18)-□NLys-(SEQ ID NO:107)             |
| 114       | (SEQ ID NO:31)-□NLys-(SEQ ID NO:107)                 |
| 115       | (SEQ ID NO:22)-□NLys-(SEQ ID NO:107)                 |
| 116,117   | (SEQ ID NO:15,18)-□NLys-(SEQ ID NO:108) <sup>a</sup> |
| 118,119   | (SEQ ID NO:15,18)-□NLys-(SEQ ID NO:109) <sup>b</sup> |

Note:

<sup>a</sup> = Phe Gly Phe Pro Lys His Leu Leu Val Asp Phe  
Leu Gln Ser Leu Ser  
(SEQ ID NO:108)

<sup>b</sup> = Leu Asp Gly Cys Leu Leu Leu Gln Met Asp Phe  
Gly Phe Pro Lys His Leu Leu Val Asp Phe Leu  
Gln Ser Leu Ser  
(SEQ ID NO:109)

63

Table 9

| Amino Acid Sequence of HIV<br>Neutralizing Epitopes<br>(SEQ ID NO) | Description of Th<br>Epitopes                  | Peptide<br>Code | Amino Acid Sequences Of Representative<br>Peptide Constructs                              |
|--|--|-----------------|---|
| ESVEINCTRPNNTRKSIRIGPGQAFYATGD<br>(SEQ ID NO:125)                  | Simplified MVF Th lib<br>(SEQ ID No:15,18)     | p2846b          | ISISEIKGVIVHKIEGILF-(cN)K-ESVEINCTRPNNTRKSIRIGPGQAFYATGD<br>T RT TR T (SEQ ID NO:126,127) |
|  | Simplified [I,L] MVF Th<br>(SEQ ID No:110,111) | p2868b          | ISLTEIRTVIVTRLETVLFF--(cN)K-ESVEINCTRPNNTRKSIRIGPGQAFYATGD<br>I I I (SEQ ID NO:128,129)   |
| KSSGKLISL<br>(SEQ ID NO:130)                                       | Simplified MVF Th<br>(SEQ ID No:15,18)         | p2942           | KSSGKLISL-(cN)K-ISISEIKGVIVHKIEGILF<br>T RT TR T (SEQ ID NO:136,137)                      |
| CNGRLYCGP<br>(SEQ ID NO:131)                                       | Simplified MVF Th<br>(SEQ ID No:15,18)         | p2937           | CNGRLYCGP-(cN)K-ISISEIKGVIVHKIEGILF<br>T RT TR T (SEQ ID NO:138,139)                      |
| (C)GTKLVCFEAA<br>(SEQ ID NO:132)                                   | Simplified MVF Th<br>(SEQ ID No:15,18)         | p2939           | (C)GTKLVCFEAA-(cN)K-ISISEIKGVIVHKIEGILF<br>T RT TR T (SEQ ID NO:140,141)                  |
| KRIVIGPQT<br>(SEQ ID NO:133)                                       | Simplified MVF Th<br>(SEQ ID No:15,18)         | p2944           | KRIVIGPQT-(cN)K-ISISEIKGVIVHKIEGILF<br>T RT TR T (SEQ ID NO:142,143)                      |
| CAGGLTCSV<br>(SEQ ID NO:134)                                       | Simplified MVF Th<br>(SEQ ID No:15,18)         | p2940           | CAGGLTCSV-(cN)K-ISISEIKGVIVHKIEGILF<br>T RT TR T (SEQ ID NO:144,145)                      |
| (C)SGRLYCHESW<br>(SEQ ID NO:135)                                   | Simplified MVF Th<br>(SEQ ID No:15,18)         | p2941           | (C)SGRLYCHESW-(cN)K-ISISEIKGVIVHKIEGILF<br>T RT TR T (SEQ ID NO:146,147)                  |

Table 10  
Immunogenicity of Representative Peptides of the Invention

| Species    | Group # | Adjuvant and Immunization Schedule  | Peptide Code                   | Description of Representative Peptide Constructs                | WPI | Log <sub>10</sub> ELISA Titer on Target Antigen | Serum Titer by Neutralization Assay (HIV-1 MN/H9) |              |  |
|------------|---------|-------------------------------------|--------------------------------|---|-----|---|---|--------------|--|
|            |         |                                     |                                |   |     |   | 50% Inhibit.                                      | 90% Inhibit. |  |
| Guinea Pig | 1       | Oil in water emulsion (0, 3, 6 WPI) | p2846 b (Seq ID Nos. 148, 149) | IS(1,4,9 PALINDROMIC Th simplified lib)LF-GG-"V3" All Consensus | 5   | 4.461   | 3972  | 425          |  |
|            |         |                                     |                                |   | 8   | 4.383   | 10276   | 535          |  |
|            |         |                                     |                                |   | 10  | 4.245   | 4245  | 1006         |  |
| Guinea Pig | 2       | Oil in water emulsion (0, 3, 6 WPI) | p2868 (Seq ID Nos. 150, 151)   | lib(1, L) - (EN)K - "V3" All Consensus                          | 5   | 4.489   | 1198  | 206          |  |
|            |         |                                     |                                |   | 8   | 4.291   | 3295  | 1092         |  |
|            |         |                                     |                                |   | 10  | 4.239   | 4233  | 1147         |  |
| Baboon     | 1       | Oil in water emulsion (0, 3, 6 WPI) | p2868 (Seq ID Nos. 150, 151)   | lib(1, L) - (EN)K - "V3" All Consensus                          | 8   | 4.375   | 948   | 152          |  |
|            |         |                                     |                                |   | 11  | over  | 23745   | 2811         |  |